Health Science
Health Science
CONTENTS
MEDICAL AND HEALTH SCIENCES
Or contact : [email protected]
CONTENTS
VOLUME I
Physiology And Maintenance 1
Osmo Hänninen, Department of Physiology, University of Kuopio, Finland
General Physiology 48
Osmo Hänninen, Department of Physiology, University of Kuopio, Finland
1. Introduction
2. Variability
3. Functional Reserves
4. Physionome
5. Functional Task Divisions
5.1. Integumentary System
5.2. Respiration
5.3. Circulation
5.4. Digestion and Other Gastrointestinal Functions
Homeodynamics 84
K. Hartiala, Pertunkatu, Turku, Finland
O. Hänninen, Department of Physiology, University of Kuopio, Finland
1. Introduction
2. Feedback and Gain
3. Intracellular Homeodynamics
4. Homeodynamics of Cell Numbers
5. Extracellular Fluid Homeodynamics
6. Environmental Temperature and Homeodynamics
7. Environmental Chemical Threats and Homeodynamics
8. Homeodynamics and Disease
9. Ecosystem Homeodynamics
1. Introduction
2. Turning the system on
3. Signaling through several pathways
4. What do the receptors do?
4.1. β-Adrenergic receptor
4.2. Vision
4.3. Smell
4.4. Taste
4.5. Viral receptors
5. GPCR families
5.1. Class A: Rhodopsin-like receptors
5.2. Class B: Secretin-like receptors
5.3. Class C: Metabotropic glutamate/pheromone receptors
5.4. Other GPCR families
6. Receptor regulation
6.1. Uncoupling
6.2. Desensitization
6.2.1. Homologous desensitization
6.2.2. Heterologous desensitization
6.3. Down-regulation
6.4. Dimerization
6.5. Clustering
7. GPCRs and human disease
8. GPCRs as a gold mine for drug development
9. Conclusions
1. Introduction
1. Introduction
2. Factors determining cell volume under steady-state conditions
3. Physiological and pathological causes of non-balanced cell volume changes
4. General mechanisms of cell volume regulation under non-steady-state conditions
4.1. Membrane transporters mediating RVD
4.2. Membrane transporters mediating RVI
4.3. Gene transcription changes in response to cell volume alterations
5. Physical and chemical signals generated by cell volume alterations: possible nature of the cell volume
sensor(s)
5.1. Mechanical signals and putative mechanosensory membrane domains
5.2. Cell volume-dependent changes in the cytoskeleton
5.3. Changes in concentration of macromolecules—macromolecular crowding
5.4. Intracellular chloride and magnesium
5.5. Intracellular ionic strength
6. Transduction of volume signal
6.1. Intracellular calcium and calmodulin
6.2. G-proteins
6.3. Protein phosphorylation
6.4. Arachidonic acid and products of its metabolism
7. Contribution of volume regulatory mechanisms to cell functions and pathological states
8. Perspectives on the studies of cell volume regulation
Thermoregulation 148
Ryszard Grucza, Institute of Sport, Warsaw, Poland
1. Introduction
2. Basic Elements of the Human Thermoregulatory System
2.1. Body Temperatures
2.2. Thermoreceptors and Thermodetectors
2.3. Thermoregulatory Centers
2.4. Thermoregulatory Effectors
3. Body Heat Balance
3.1. Metabolic Heat Production
3.2. Radiation
3.3. Convection
3.4. Conduction
3.5. Evaporation
4. Thermoregulatory Reactions to Heat and Cold
4.1. Skin Blood Flow
4.2. Sweating
4.3. Nonshivering Thermogenesis and Brown Adipose Tissue
4.4. Shivering Thermogenesis
5. Body Heat Loads
5.1. Thermal Comfort
5.2. Heat Exposure
5.3. Exercise
5.4. Cold Exposure
6. Models of the Human Thermoregulatory System
7. Efficiency of Human Thermoregulation
8. Gender Differences in Thermoregulation
9. Acclimation and Acclimatization
10. Thermoregulation in Children
11. Other Aspects of Thermoregulation
11.1. Hyperthermia
11.2. Malignant Hyperthermia
11.3. Fever
11.4. Hypothermia
1. Introduction
2. Physiological and pathological pain
3. Pain definition
4. Classification of Pain
5. Central Pain Pathways
6. Withdrawal Reflex and Avoidance Behavior Induced by Noxious Stimulation
7. Regulation of Pain Transmission in the Central Nervous System
8. Functional and Structural Changes in the Pain Tracts
9. Responses of Peripheral Nociceptors to Tissue Injury and Inflammation
1. Introduction
1.1. Repair vs. Regeneration
1.2. Embryogenesis and Fetal Healing
1.3. Prototypic Wound
1.4. Main Cellular Effectors
1.5. Cytokines and Growth Factors
2. Phased Healing Response
2.1. Inflammatory Phase: Hemostasis and Inflammation
2.1.1. Hemostasis
2.1.2. Inflammation
2.2. Migratory Phase: Angiogenesis, Fibroblast Migration and Proliferation, Epithelialization, and
Neuronal Repair
2.2.1. Angiogenesis
2.2.2. Fibroblast Migration and Proliferation
2.2.3. Epithelialization
1. Introduction
2. Learning by Classic Conditioning
2.1. Habituation
2.2 Sensitization
2.3. Long-Term Potentiation (LTP) and Long-Term Depression
3. Memory
3.1. Short Term Memory (STM)
3.2 Long Term Memory (LTM)
3.3. Consolidation of Memory
4. Neural Mechanisms of Memory
4.1. Mechanism Involved in Short Term Memory
4.2. Mechanisms Involved in Long Term Memory
5. Brain Areas Involved in Memory
6. Amnesia
1. Introduction
2. Enzymes as Biological Catalysts
2.1. Factors Affecting Activity
2.2 Active Site
2.3 Enzyme Kinetics
2.4. Specificity
2.5. Mechanism of Action
2.6. Regulation of Enzyme Activities
3. Cofactors
4. Enzymes in the Cell
5. Enzyme Turnover
6. Enzyme Nomenclature
6.1. Reaction Types
6.2. Isoenzymes
7. Clinical and Biotechnological Applications of Enzymes
7.1. Clinical Enzymology
7.2. Biotechnological Applications
1. Background
2. Enzyme Specificity
3. General Features to Increase the Reaction Rate
4. Basic Catalytic Mechanisms
5. Stabilization of the Transition State
6. Transition State Analogs
7. Enzymic and Metabolic Equilibria
Index 309
VOLUME II
On The Determination Of Enzyme Structure, Function, And Mechanism 1
Glumoff T.,University of Oulu, Finland
1. Introduction
2. Structure Determination Techniques
2.1. X-ray Crystallography
2.1.1. General
2.1.2. Crystallization of Enzymes
2.1.3. X-ray Diffraction Experiments
2.1.4. The Phase Problem
2.1.5. Crystallographic Calculations
2.2. Nuclear Magnetic Resonance Spectroscopy (NMR)
3. Relationship of Enzyme Structure with Enzyme Chemistry and Mechanism
3.1. General
3.2. Case: Lignin Peroxidase
4. Future Considerations
Enzymes Of Digestion 14
Senol Dane, Atatürk University, Medical Faculty, Department of Physiology, Erzurum, Turkey
Osmo Hänninen, Department of Physiology, University of Kuopio, Finland
1. Introduction
2. Hydrolysis
3. Enzymes of Digestion According to their Sites of Secretion
3.1. Ptyalin (α- amylase)
3.2. Lingual Lipase
3.3. Enzymes Secreted from Gastric Glands
3.3.1. Pepsin
3.3.2. Gastric Lipase
3.4. Pancreatic Digestive Enzymes
3.4.1. Amylase
3.4.2. Lipase
3.4.3. Phospholipase A2
3.4.4. Carboxylesterase
3.4.5. Endopeptidases
3.4.6. Carboxypeptidases
3.4.7. Nucleases
3.5. Enzymes of Intestinal Mucosa
3.5.1. Aminopeptidases
3.5.2. Dipeptidases
3.5.3. Diesterases
3.5.4. Nucleotidases
3.5.5. Oligo- and disaccharidases
4. Conclusion
Metabolism Of Oxygen 30
Mika Venojärvi, Department of Physiology, Institute of Biomedicine University of Kuopio, Kuopio,
Finland and Medical Laboratory Technology, Turku University of Applied Sciences, Turku, Finland.
1. Introduction
2. Oxygen chemistry
2.1. Oxygen molecule
2.2. Singlet oxygen
2.3. Superoxide, hydrogen peroxide and hydroxyl radical
1. Introduction
2. HIF: transcriptional regulator of hypoxic responses
3. Oxygen-dependent regulation of HIF
3.1. Oxygen-dependent regulation of HIFα stability
3.2. Oxygen-dependent regulation of HIF transcriptional activity
4. Reactive Oxygen Species (ROS) and cellular responses
5. Oxygen and disease progression
5.1. Solid tumors
5.2. Myocardial Ischemia
1. Introduction
2. Absorption of Xenobiotics
3. Detoxication and Bioactivation
3.1. Oxidation of Xenobiotics
3.1.1. Cytochrome P-450
3.1.2. Other Oxidases
3.2. Reduction
3.3. Hydrolysis
3.4. Conjugation Reactions
3.4.1. Glucuronide Synthesis
3.4.2. Amino Acid Conjugations
3.4.3. Glutathione Conjugations
3.4.4. Sulfonic Acid Conjugations
3.4.5. Acetylation and Methylation
4. Excretion of Metabolites
1. Historical Background
2. Enzyme Classification
3. Enzyme Production
3.1. Microbial Production Strains
3.2. Enzyme Production by Microbial Fermentation
4. Protein Engineering
5. Enzyme Technology
6. Large-Scale Enzyme Applications
6.1. Detergents
6.2. Starch Hydrolysis and Fructose Production
6.3. Drinks
6.4. Textiles
6.5. Animal Feed
6.6. Baking
6.7. Pulp and Paper
6.8. Leather
7. Specialty Enzymes
7.1. Enzymes in Analytics
7.2. Enzymes in Personal Care Products
7.3. Enzymes in DNA Technology
8. Enzymes in Fine Chemical Production
8.1. Enantiomerically Pure Amino Acids and Aspartame
8.2. Rare Sugars
8.3. Semisynthetic Penicillins
8.4. Lipase-Based Reactions
8.5. Asymmetric Synthesis
8.6. Enzymatic Oligosaccharide Synthesis
9. Future Trends in Industrial Enzymology
1. Nutrition
1.1. Body Composition
1.2. Nutritional Needs
1.3. Over and Undernutrition
1.4. Nutritional Genomics
2. Digestion
2.1. Digestion of Macronutrients
2.2. Digestion of Micronutrients
2.3. Malabsorption
2.4. Intestinal Microflora
1. Introduction
2. General Structure of Digestive Tract
2.1. Mouth
2.2. Stomach
2.3. Intestine
2.4. Liver and Pancreas
2.5. Microbes Contribute to Digestion
3. Carnivores
3.1.Cat and Dog
4. Herbivores
4.1. Rabbits
4.2. Guinea Pigs
4.3. Horses
4.4. Cow and Other Ruminants
5. Birds
1. Introduction
2. Physico-Chemical Properties of Fatty Acids
3. Biosynthesis of Fatty Acids
4. Classification and Biological Function of Fatty Acids
5. Fatty Acids as Constitutional Components of Lipids
6. Physiological Roles of Fatty Acids
7. Milk Lipids and Developing Brain
8. Pathophysiology of Fatty Acids
9. Therapeutic Use of Polyunsaturated Fatty Acids
1. Introduction
2. Food Safety and Various Eating Patterns
3. Plant-Based Dietary Patterns and Physiological Health Promotion
4. Plant-Only Diets and Health Risk Control
5. Dietary Guidelines for Vegetarians
6. Divergence in Values About Eating
1. Introduction
2. Nutrition and Digestion of Sterols
2.1. Sterols in the Diet
2.1.1. Cholesterol
2.1.2. Non-cholesterol Sterols
2.2. Mechanism of Sterol Absorption
2.2.1. Micellar Phase
2.2.2. Enterocytar Phase
3. Sterols in the Human Body
3.1. Turnover of Sterols
3.2. Sterols in the Plasma
3.2.1. Cholesterol Level in Plasma
3.2.2. Concentrations of Non-cholesterol Sterols in Plasma
3.3. Lipoprotein Metabolism
3.4. Cellular Homeodynamics of Cholesterol
3.4.1. Cholesterol Biosynthesis
3.4.2. Cellular Trafficking of Cholesterol
3.4.3. Cholesterol from and to the Cell
Index 303
VOLUME III
Renal Excretion 1
László Rosivall, Department of Pathophysiology, Semmelweis University, Hungary
Shahrokh MirzaHosseini, Semmelweis University, Faculty of Medicine, Institute of Pathophysiology,
Nephrology Research and Training Center, Hungarian Academy of Sciences. Avicenna College,
International Education Center, Budapest, Hungary.
1. Introduction
2. Functional Anatomy and Histology of the Kidneys
3. Nephron
3.1. Glomerulus
3.2. Tubules
4. Renal Blood Vessels
5. Bladder and Urination
6. Urine Composition
1. Introduction
2. Renal General Functions
3. Body Fluid Compartments
4. Juxtaglomerular Apparatus (JGA) Releases Renin
5. Glomerular Ultrafiltration (GFR) and Its Determination
6. Composition of the Glomerular Filtrate
7. Tubular Filtrate Processing
7.1. Reabsorption
1. Introduction
2. Water Balance
3. Water Deprivation
4. Minimum Daily Water Intake
5. Antidiuretic Hormone
6. Synthesis and Mechanism of Action of ADH
7. Ion Imbalances
7.1. Hyponatremia
7.2. Hypernatremia
7.3. Hypokalemia
7.4. Hyperkalemia
1. Introduction
2. Excretion of Creatinine
3. Excretion of Urea
4. Renal Failure
4.1. Acute Renal Failure (ARF)
4.1.1. Parenchymal Acute Renal Failure
4.2. Chronic Renal Failure (CRF)
1. Introduction
2. Fishes
2.1. Hagfishes
2.2. Lampreys
2.3. Elasmobranchs
2.4. Marine Teleosts
2.5. Freshwater Teleosts
2.6. Euryhaline Teleosts
3. Amphibians
4. Reptiles
5. Birds
Endocrinology 47
Juhani Leppäluoto, Department of Physiology, University of Oulu, Finland
1. Introduction
1. Introduction
2. Chemical nature of hormones
2.1. Peptide and protein hormones
2.2. Amino acid and fatty acid derivatives
2.3. Cholestrol-derived hormones
3. Hormone transport in blood
4. Hormones as universal and specific regulators
5. Hormone receptors
5.1. Cell surface receptors
5.1.1. G-protein coupled receptors (GPCRs)
5.1.1.1. cAMP signalling
5.1.1.2. cGMP signalling
5.1.1.3. IP3 and DAG signalling
5.1.2. Protein tyrosine kinase-linked receptors (PTKRs)
5.2. Intracellular and nuclear receptors
5.3. Silent receptors
5.4. Orphan nuclear receptors
5.5. Receptor isoforms
5.6. Receptor recycling and degradation
5.7. Receptor desensitization
5.8. Receptor mutations
6. Feedback systems
7. Decay of hormones
8. Endocrine disruptors
9. Evolution of hormones
1. Introduction
2. Action Mechanisms of Glucocorticoids
3. Corticosteroid Receptors
4. Neural and Neuroendocrine Control of Glucocorticoid Secretion
5. Glucocorticoids as a Biological Substrate of Reward
6. Role of Glucocorticoids in Affective Illness
7. Neurotoxicity of Glucocorticoids
1. Introduction
2. Melatonin as Pineal Hormone of Darkness
3. Melatonin in Other Tissues
4. Circadian Secretion Pattern of Melatonin
5. Seasonal Secretion of Melatonin
6. Metabolism of Melatonin
7. Melatonin Receptors
8. Biological Action Profile of Melatonin
8.1. Melatonin and Sleep
8.2. Melatonin as Antioxidant and Cancer
8.3. Melatonin, Mental Health and Aging
9. Future Perspectives
10. Conclusions
1. Introduction
2. Adaptation of the Heart to Increased Load
3. Discovery of Cardiac Hormones
4. Physiological Effects of Cardiac Natriuretic Peptides (ANP and BNP)
5. Natriuretic Peptide Receptors
6. Regulation of ANP and BNP
7. Therapeutic Use of Cardiac Hormones
8. Diagnostic Use of Cardiac Hormones
1. Introduction
2. Why did a tropical man move to cold climate areas?
3. Does modern man experience cold?
4. Physiological heat production
4.1. Muscle activity and heat production
4.2. Nonshivering thermogenesis and hormones
5. Thyroid hormones in cold
6. Catecholamines and brown adipose tissue
7. Frost bites
Respiration 130
Y.J. Salorinne, Department of Clinical Physiology and Nuclear Medicine, Helsinki University Hospital
and Helsinki University Medical Faculty, Helsinki, Finland
P. Haapalahti, Department of Clinical Physiology and Nuclear Medicine, Helsinki University Hospital
and Helsinki University Medical Faculty, Helsinki, Finland
1. Introduction
2. Four Types of Surfaces for Gas Exchange
2.1. Body Surfaces
2.2. Gills
2.3. Tracheal System
2.4. Lungs
3. Air Quality and Respiration
4. Human Lung Pathophysiology
5. Oxygen Delivery
6. Haemoglobin Engineering
7. Control of Breathing
1. Introduction
2. Lung Structure and Volumes
3. Terminal Respiratory Unit
4. Pulmonary and Alveolar Ventilation
5. Gas Exchange
6. Distribution of Ventilation and Perfusion
7. Mismatch of Ventilation and Perfusion
8. Smoking and Respiration
1. Introduction
2. Dynamics of Respiration
3. Control of Respiration
1. Introduction
1. Introduction
2. Functional Organization of the Circulatory System
2.1. The Two Separate Pumps of the Circulation: Left Heart and Right Heart
2.2. Functional Units of Systemic Blood Vessels Coupled in Series
2.3. Blood Vessels Coupled in Parallel
2.4. Structural Properties of the Vascular Wall
3. List of Physiological Functions Coupled to the Vascular System
4. Hemodynamics: Biomechanical Characteristics of the Circulation
4.1. Biomechanical Properties of the Blood: Blood Rheology
4.2. Biomechanics of the Vascular Wall: Stress, Strain, Elasticity
4.3. Blood Pressure and Flow: Vascular Resistance
4.4. Biomechanics of the Heart: the Cardiac Cycle
5. Physiological Control of Circulation
5.1. Local Control Mechanisms
5.2. Systemic Control Mechanisms
6. Hints to Maintain Healthy Circulatory Functions
1. Introduction
2. Elementary Hemodynamics and Wall Mechanics
2.1. Laminar and Turbulent Flow
2.2. Hydrodynamic Resistance
2.3. Blood Viscosity
2.4. Parameters of Artery Wall Elasticity
3. Biological Design of Arteries
3.1. Arterial Tree
3.2. Geometric Design of Arterial Segments
3.3. Arterial Viscoelasticity. Effects of Smooth Muscle Contraction-relaxation
3.4. Histologic Design
3.5. Angiogenesis, Remodeling of Arteries
4. Cytophysiology of Artery Wall Components
4.1. Arterial Smooth Muscle Cells
4.2. Endothelial Cell
4.3. Connective Tissue
5. Pressure in Arteries
5.1. Measurement of Arterial Pressure
5.2. Arterial Pressure Curve
5.3. Values of Arterial Blood Pressure
5.4. Arterial Pressure Wave
6. Blood Flow in Arteries
6.1. Measurement of Arterial Blood Flow
6.2. Pulsatile Flow
7. Different Segments of the Arterial Tree
7.1. Windkessel Arteries
7.2. Distributing (large muscular) Arteries
7.3. Resistance Arteries
1. Introduction
2. Survey of Physiological Functions of the Venous System
2.1. Collecting Blood Conduit Network System with Unidirectional Valves
2.2. Selective Barrier Function
2.3. Regulated Capacitance Function: Adaptive Distribution of the Circulating Blood Volume
2.4. Maintenance of the Filling Pressure of the Heart
2.5. Supporting Orthostatic Tolerance
2.6. Postcapillary Resistance
2.7. Angiogenesis
2.8. Synthesis of Bioactive Substances in the Vein Wall
2.9. Immune Functions: Organ-Specific Distribution of Circulating Effector Lymphocytes
2.10. Cooperation between Venular Endothelium and Polymorphonuclear Leukocytes (PMNL)
2.11. Inhibition of Thromboembolic Reactions
2.12. Special Regional Functions
3. Central Venous Pressure
4. Aspects of Maintaining Healthy Venous Functions
Microcirculation 260
Sergey A. Polenov, Pavlov Institute of Physiology, St. Petersburg, Russia
1. Introduction
2. Classification and Structure of Microvessels
3. Control of Microcirculation
3.1. General Considerations
1. Introduction
1.1. Historical Perspectives
1.2. Principles of Rheology
1.3. Definition of Hemorheology
2. Rheology of Blood
2.1. Structure of Blood
2.2. Blood Viscosity, ex vivo
2.3. Determinants of Blood Fluidity
2.3.1. Plasma Viscosity
2.3.2. Hematocrit Value
2.3.3. Contribution of Red Blood Cell Rheologic Behavior to Blood Fluidity
2.4. Red Blood Cell Deformability
2.5. Red Blood Cell Aggregation
2.6. Contribution of White Blood Cells to Blood Flow at Tissue Level
3. Clinical Aspects of Blood Rheology
3.1. Hematocrit as a Determinant of Whole Blood Viscosity
3.2. Pathologic Alterations of Red Blood Cell Mechanical Properties
3.2.1. Effects on Red Blood Cell Deformability
3.2.2. Effects on Red Blood Cell Aggregability
3.2.3. Role of Oxidant Stress in Hemorheological Disturbances
3.2.4. Role of White Blood Cell Activation in Hemorheological Disturbances
4. Role of Hemorheology in Hemodynamics
4.1. Flow Behavior of Blood in Cylindrical Tubes
4.2. Flow Behavior of Blood in vivo
4.2.1. Role of Red Blood Cell Deformability
4.2.2. Role of Phase Separation and Red Blood Cell Aggregation
4.2.3. Role of Vascular Control Mechanisms
4.3. Importance of Hemorheological Factors for Tissue Perfusion
Index 309
VOLUME IV
Locomotion In Sedentary Societies 1
O. Hänninen, Department of Physiology, University of Kuopio, Finland
M. Atalay, Department of Physiology, University of Kuopio, Finland
1. Introduction
2. Physiological Responses to Exercise
2.1. Gliding Filaments
2.2. Measurement of leisure-time physical load
2.2.1 Absolute Intensity
2.2.2 Relative Intensity
3. Physical Activity and Health
3.1. Quantity of Recommended Physical Activity
3.1.1 Exercise Training and Exercise Prescriptions
3.2. Benefits of Outdoor Activities
3.3. Physical Exercise and Ageing
3.4. Physical Exercise and Disease
3.4.1 Cardiovascular Disease
3.4.2 Diabetes
3.4.3 Cancer
3.4.4 Physical Activity and the Physically Disabled
3.4.5 Obesity
4. Ergonomy in the Information Society
4.1. Static Sitting
4.2. Dynamic Sitting and Exercises
5. Nutrition and Musculoskeletal System
5.1. Building of Bones and Tendons
5.2. Building of Muscles and Nerves
6. Negative Effects of Training
6.1. Over-training
6.2. Soreness, Abrasions and Traumas
7. Doping
1. Introduction
2. Voltage sensor of ECC
2.1. Voltage dependence
2.2. Intra-membrane charge movement
2.3. Molecular identification of the voltage sensor
3. Calcium release channel of the SR
3.1. RyR isoforms in skeletal muscle
3.2. Endogenous regulators of RyR
3.3. Pharmacological modulators of ECC
4. Control of sarcoplasmic calcium release
4.1. Calcium-induced calcium release
4.2. Mechanical coupling of DHPR-s and RYR-s
4.3. Dual control of SR calcium release
4.4. Time course of SR permeability increase during excitation
4.5. Current understanding of the events in ECC
5. Altered ECC in disease
1. Introduction
2. Motor Control
2.1. Focused Attention
2.1.1 Voluntary Control of Movements
2.2. Subsidiary Movements
2.2.1. Anticipatory Movements
2.2.2 Automatic Motor Programs
2.3. Cooperation of Voluntary and Subsidiary Control
2.4. Proprioception
2.4.1 Pain and Proprioception
3. Postural Control
4. Motor Control of the Lumbar Spine
4.1. Function of the Lumbar Spine
4.1.1 Segmental
4.1.2. Kinetic Chain
4.1.3. Feedback Control
4.1.4. Feed-forward Control
5. Lumbar Disorders
5.1. Classification of Lumbar Disorders
5.2. Pathophysiology
5.2.1 Disc Herniation
5.2.2 Lumbar Spinal Stenosis
6. Pain and Motor Control
7. Future Perspectives
1. Introduction
2. Skeletal Muscle
2.1. Sliding Filaments
2.2. Skeletal Muscle Fiber Types
2.3. Muscle Fitness
2.4. Adaptation of the Skeletal Muscle to Exercise
2.4.1. Adaptation to Endurance Exercise
2.4.2. Adaptation to Short-Duration, High-Intensity Exercise
2.5. Energy Metabolism of the Skeletal Muscle
2.5.1. Alactic Mechanisms
2.5.2. Glycolysis
2.5.3. Oxidative Phosphorylation
2.5.4. Recovery and Oxygen Debt
3. Cardiovascular Adaptation due to Exercise
3.1. Muscle Blood Flow During Exercise
3.2. Cardiac Functions
3.2.1. Heart Rate
3.2.2. Stroke Volume
3.2.3. Cardiac Output
3.3. Blood Pressure
3.4. Changes in Blood During Exercise
3.5. VO 2 max , the Best Measure of Cardiovascular Capacity
4. Respiratory Regulation During Exercise
4.1. Increased Alveolar-Capillary PO2 Gradient, Blood Flow, and CO2 Removal
4.2. Changes in Respiratory Quotient (RQ) During Exercise
4.3. Control of Ventilation During Exercise
4.4. Exercise Capacity Limiting Factor
5. Fatigue
6. Conclusion
1. Introduction
2. Bipedal being
3. Balance
4. Limping
5. Overweight and osteoarthritis
6. Joint pains
6.1. Toes
6.2. Ankles
6.3. Knees
6.4. Hips and pelvis
6.5. Back, lordosis, kyphosis and scoliosis
6.6. Neck/shoulder pain and headache
6.7. Arms
7. Exercise, prevention of limping and maintaining motility
8. Conclusions
Functional Morphological And Physiological Aspects Of Human Locomotion And Posture 140
Witte H., Technische Universität, Ilmenau, Germany, and Friedrich-Schiller-Universität, Jena, Germany
Klauer G., Friedrich-Schiller-Universität, Jena, Germany
Schumann N.P., Friedrich-Schiller-Universität, Jena, Germany
Scholle H.C., Friedrich-Schiller-Universität, Jena, Germany
1. Introduction
2. Physiology and Pathophysiology of Sitting
3. Dynamism to Sitting
4. Mental Strain and Sitting
5. Sitting at Schools
6. Deterioration of Muscle Fitness and Everyday Life
7. Osteoporosis
8. Metabolic Problems in Sedentary Life
Neurophysiology 197
Simo S. Oja, University of Tampere Medical School, Finland, and Tampere University Hospital, Finland
Pirjo Saransaari, University of Tampere Medical School, Finland, and Tampere University Hospital,
Finland
1. Introduction
2. Sympathetic and parasympathetic divisions of the autonomic nervous system
3. Autonomic neurotransmitters
4. Autonomic nervous functions
4.1. Autonomous regulation of heart and blood vessels
4.2. Regulation of arterial blood pressure
4.3. Autonomous neural regulation during postural changes and physical activity
4.4. Autonomous regulation of the gastrointestinal system
5. Changes in autonomous regulation
5.1. Changes in autonomous neural regulation with aging
5.2. Association between gender and autonomous neural regulation
5.3. Association between body constitution and autonomous neural regulation
5.4. Association between physical fitness and autonomous neural regulation
5.5. Clinical significance of autonomous Dysregulation
1. Introduction
1.1. Nerve Cells
1.2. Glial Cells
2. Resting Membrane Potential
3. Action Potential
4. Synapses
5. Neurotransmitter Actions
6. Neuromuscular Junctions
7. Synaptic Receptors
8. Intracellular Messengers
1. Introduction
2. Acetylcholine
3. Synthesis and Breakdown of Amine Transmitters
4. Dopamine
5. 5-Hydroxytryptamine
6. Histamine
7. Purine Transmitters
8. Synthesis, Breakdown and Transport of Amino Acid Transmitters
9. Glutamate
9.1. Ionotropic Glutamate Receptors
9.2. Metabotropic Glutamate Receptors
9.3. Glutamate Receptors and Neuronal Damage
10. γ-Aminobutyrate (GABA)
10.1. GABAA Receptors
10.2. GABAB Receptors
11. Glycine
12. Peptide Transmitters and Modulators
13. Nitric Oxide and Carbon Monoxide
1. Introduction
2. The Possible explanation of mechanisms of phantom pain.
2.1 Peripheral mechanisms
2.2 Central mechanisms
2.3 Psychological mechanisms
3. The treatment of phantom pain.
3.1 Noninvasive therapy
3.2 Invasive therapy
1. Introduction
2. Circadian Rhythms are Endogenous
3. Entrainment
4. Rhythms in Plants
5. Rhythms in Animals
6. Suprachiasmatic Nucleus (SCN)
7. Projections from the SCN
8. Rhythms outside the SCN
9. Clock Genes
10. Measurement of the Circadian Rhythms
11. Melatonin
12. Human Performance and Circadian Rhythm
13. Jet Lag
14. Shift Work
15. Seasonal Depression
Index 311
VOLUME V
Sleep 1
Dag Stenberg, Institute of Biomedicine/Physiology, University of Helsinki, Finland
1. Introduction
2. Definition of Sleep
3. Amount and Timing of Sleep
4. Sleep Stages and the Structure of Nocturnal Sleep
5. Regulation of Sleep
5.1. Sleep Need and Homeostasis
5.2. Circadian Regulation of Sleep
5.3. Overall Regulation of Sleep
6. Disorders of Sleep
6.1. Insufficient Sleep―Insomnia
6.2. Excessive Sleep - Hypersomnia - Excessive Daytime Sleepiness
6.3. Narcolepsy
6.4. Sleep Apnea
6.5. Parasomnias
7. Brain and Sleep
7.1. Classical Concepts
7.1.1. Hypothalamus
7.1.2. Reticular Formation
7.1.3. Encéphale Isolé, Cerveu Isolé and the REM Sleep Generator of the Pons
7.2. Neuronal Activity during Sleep
7.3. Waking Centers
7.3.1. Locus Coeruleus and Noradrenaline
7.3.2. Posterior Hypothalamus and Histamine
7.3.3. Midline Neurons and Serotonin
7.3.4. Basal Forebrain, Pontomesencephalic Nuclei and Acetylcholine
7.3.5. Lateral Hypothalamus and Hypocretin/Orexin
7.3.6. Dopamine System
1. Introduction
2. Sensory Signals and Food Intake
3. Gastrointestinal Neural Signals and Food Intake
4. Gastrointestinal Hormones and Food Intake
5. Nutrient Blood Levels in Regulation
6. Sympathetic Nervous System and Obesity
7. Adipose Tissue Feedback in Regulation
8. Food Intake and Centers in the Brain
9. Psyche and Nutrition
10. Regulation of Drinking
11. Social Eating and Drinking
12. Culture and Selecting Foods
13. Physical Activity and Food Intake
14. Eating and Drinking Disorders
1. Introduction
2. General adaptation syndrome
2.1. Alarm reaction
2.2. Resistance
2.3. Exhaustion
3. Anatomy of stress and physiological mechanisms
3.1. Hypothalamic-pituitary-adrenal axis
3.2. Sympathetic-adrenal-medullary axis
3.3. Feedback control
3.4. Stress hormones
3.5. Stress-induced analgesia
4. Differences in stress response
4.1. Interindividual differences
4.2. Age differences
1. Introduction
2. Needs for pleasure
2.1. Centers for Pleasure
2.2. Neuroanatomy of the Reward Cascade
2.3. Cloninger’s Typology
3. Reward Deficiency Syndrome
3.1. Dopamine Receptors
3.2. Addictive Behavior
3.3. Alcoholism
3.4. Treatment of the Reward Deficiency Syndrome
3.5. Drug Abuse
4. Love
4.1. Neurophysiology of Love
4.2. Chemistry of Love
4.3. Sexual and Passion Behavior
4.4. Pleasure and Pain
1. Introduction
1.1. Importance of Photosynthesis for Life on Earth
1.2. Discovering the Total Reaction of Plant Photosynthesis
1.3. General Principles of the Mechanism of Photosynthesis
2. Structures, Properties and Natural Occurrence of Chlorophylls
3. Chlorophylls as Redox Pigments in the Photosynthetic Reaction Centers
3.1. Structure of the Reaction-Center Complex of Photosynthetic Purple Bacteria
3.2. Organization of Chlorophyll and Other Coenzymes in the Photosynthetic Reaction-Centers of
Oxygenic Organisms
3.3. Earlier Studies of the Chlorophyll Special-Pair as Reaction-Center Chlorophyll
3.4. Chlorophyll Enolates and 132 (S)-Epimers as Potential Reaction-Center Pigments
4. Functions of Chlorophylls in the Light-Harvesting Antenna Systems
4.1. Organization of Chlorophylls and Carotenoids in Various Light-Harvesting Complexes
4.2. Mechanisms of Energy Transfer in Photosynthetic Systems
5. Opportunities Offered by Chlorophyll and Photosynthesis Research
1. Nitrogen-Fixing Organisms
2. Importance of Nitrogen Fixation
2.1. Inputs to the Ecosystems
2.2. Methods to Measure Nitrogen Fixation
3. The Rhizobium–Legume Symbiosis
3.1. The Rhizobia
3.2. Establishment of the Symbiosis
3.3. Functioning of the Root Nodule
4. Evolution and Ecology
5. Applications
5.1. Agronomy and Forestry
5.2. Biotechnology
6. Future prospects
1. Introduction
2. Indole-3-Acetic Acid
2.1. IAA Biosynthesis
2.2. Physiological Role of IAA
2.3. IAA Mode of Action
3. Gibberellins
3.1. GA Biosynthesis
3.2. Physiological Role of GA
3.3. GA Mode of Action
4. Abscisic Acid
4.1. ABA Biosynthesis
4.2. Physiological Roles of ABA
1. Introduction
2. Allelopathic Interactions in Plant Communities of Natural Ecosystems
2.1. Grassland Communities
2.1.1. Mechanism of Dominant Vegetation
2.1.2. Mechanism of Plant Succession
2.1.3. Invasion Mechanism of Alien Species
2.2. Fern Community
2.3. Forest Communities
2.3.1. Dominance of Woody Vegetation in Arid and Semiarid Zones
2.3.2. Dominance of Woody Trees in Humid Zones
2.3.3. Invasion of Trees into Grassland
3. Allelopathy in Aquatic Ecosystem
4. Allelopathic Interactions in Agroecosystems
4.1. Autointoxication Causing Yield Reduction of Continuous Monoculture of Crops
4.1.1. Rice Plants
4.1.2. Sugarcane Plantation
4.1.3. Asparagus Plants
4.2. Allelopathic Effect on Crop Productivity
4.2.1. Agronomic Crops
4.2.2. Conventional- and No-tillage Crops
4.3. Allelopathic Regulation of Understory Species in Forest Plantation
5. Allelopathy in Sustainable Agriculture
5.1. Interaction in Agronomic Crops Inter-cropping
5.2. Interaction in Pasture and Forest Inter-cropping
5.3. Interaction in Cover Grass and Orchard Trees Inter-cropping
6. Allelopathy in Relation to Environmental Complexity
6.1. Drought Stress
6.2. Nutrient Deficiency
6.3. Dynamics of Allelopathic Compounds in Soils
7. Future Allelopathic Research
7.1. Allelopathic Compounds in Rhizosphere Soils
7.2. Application of Naturally Occurring Allelopathic Compounds to Agricultural Practice
7.3. Approach of Molecular Biotechnology to Allelopathy
8. Conclusions
Phenology Of Trees And Other Plants In The Boreal Zone Under Climatic Warming 207
Heikki Hänninen, Department of Ecology and Systematics, University of Helsinki, Finland
1. Introduction
1.1. Global Change
1.2. Phytotoxic Air Pollutants
2. Ozone as Environmental Pollutant
2.1. Ozone Formation and Concentrations
2.2. Critical Ozone Doses for Plants
3. Plant Responses to Ozone
3.1. Ozone Uptake by Plants
3.2. Biochemical Responses
3.2.1. Antioxidative Systems Affording Protection from Ozone
3.2.2. Other Biochemical Defense Systems
3.2.3. Ozone-Induced Increase in Phenolic Compounds
3.3. Physiological Responses
3.3.1. Photosynthesis and Respiration
3.3.2. Stomatal Conductance
3.3.3. Growth and Carbon Allocation
3.4. Structural Responses and Visible Injuries
3.4.1. Structural Responses
3.4.2. Visible Injuries in Foliage
3.4.3. Role of Ethylene in Formation of Visible Injuries
3.4.4. Programmed Cell Death
3.5. Ozone and Forest Trees
3.5.1. Impact on Forest Ecosystems
3.5.2. Effects of Ambient Ozone on European Forests
3.5.3. Effects of Ambient Ozone on Forest Trees in North America
3.5.4. Sensitivity of Young Seedlings versus Mature Trees
3.5.5. Birch is a Sensitive Model Plant in Ozone Research
4. Combined Action of Air Pollutants and Other Environmental and Climatic Factors in Plants
4.1. Air Pollutant Interactions
4.1.1. Ozone and CO2 Interactions
4.2. Environmental Interactions
4.2.1. Impact of Water Conditions on Plant Responses
4.2.2. Role of Nutrient Availability in Plant Responses
4.2.3. Impact of Temperature on Plant Responses
4.2.4. Impact of Light Regimes on Plant Responses
4.2.5. Interactions with Biotic Stress Factors
4.3. Disturbed Seasonality due to Global Change
1. Introduction
2. Ecosystem and Host Plant Level Disturbances in Polluted Areas
3. Responses of Various Plant Feeder Groups to Environmental Changes
4. Effects of the Most Important Air Pollutants on Plant-Feeding Insects
Index 259
VOLUME VI
Global Perspectives In Health 1
Boutros-Pierre Mansourian, Former Director, Research Policy and Strategy Co-ordination, World Health
Organization, Geneva, Switzerland
1. Introduction
2. Definitions and Concepts
3. Critical questions in health
3.1. Factors that determine health
3.2. How to care for health
3.3. Global health outlook
4. The measurement of health
4.1. The concept of “health”
4.2. Measurement and decision-making
4.3. The concept of the indicator
4.4. The scope and taxonomy of indicators
4.4.1. The WHO classification of indicators
4.4.2. The need for a taxonomy
4.4.3. A possible taxonomy of indicators
4.5. The design and validation of indicators
4.5.1. Indicator design
4.5.2. Validation of indicators
4.5.3. A new paradigm for the design and validation of health indicators
4.5.3.1. Problem-Oriented Approach
4.5.3.2. Conceptual Modeling
4.5.3.3. Indicator Production
4.5.3.4. Data Availability
4.5.3.5. Validation
4.6. The “indicator family” concept
4.7. The “indicator system” concept
5. Health in a global context
5.1. Health and overall development
5.2. Essential health-related services
5.2.1. Immunization
5.2.2. Childhood illness
5.2.3. Reproductive issues
5.2.4. Nutrition issues
5.2.5. School health and nutrition
5.2.6. Re-emerging or new communicable diseases
1. Introduction
2. The major determinants of health
3. Indicators
3.1 The "indicator family" concept
3.2 Design of indicators as families of indicators
3.3 The integrated indicator "system" concept
4. Data for indicators
4.1 Aggregation and disaggregation of data
5. Interactions
1. Introduction
2. Evolutionary Adaptations
3. Patterns of Migration
4. Domestication of Livestock and Human Cohabitation
5. Ecological Modifications and Biodiversity
6. Final Considerations
1. Introduction
2. Domestic Environment
2.1. Water and Sanitation
2.2. Domestic Pests
2.3. Food Contamination
2.4. Air Pollution from Domestic Sources
2.5. Tuberculosis
3. Local Environment
3.1. Air Pollution
3.1.1. Suspended Particulate Matter
3.1.2. Air Pollutants
3.1.3. Toxic Air Pollutants
3.2. Hazardous Waste
3.2.1. Plastics
3.2.2. Asbestos
3.3. Water Pollution
3.3.1. Domestic Wastes and Sewage
3.3.2. Industrial Wastes and Effluents
3.4. Diseases Associated with Polluted Water
4. Global Factors
4.1. Ozone Depletion
4.1.1. The Ozone Hole
1. Introduction
2. General Health Determinants
2.1. Framework Conditions
2.2. Individual Health Determinants
3. Health Interventions
3.1. The Health Care System
3.2. Measures and Programs in the Process of Health and Disease
3.3. Health Management
4. Outlook
1. What is Epidemiology?
2. Purposes of Epidemiology
3. Defining and Measuring Health and Disease
3.1. Disease Nomenclature and Classification
3.2. Counting Disease
3.3. Severity of Disease
3.3.1. Mortality
3.3.2. Morbidity
3.3.3. Composite Measures Combining Morbidity and Mortality
4. Descriptive Epidemiology
4.1. Infectious Disease Triad
4.2. Descriptive Epidemiology Triad
4.3. Health Indicators
5. Epidemiological Approaches to Understanding Causal Relations
5.1. Concept of Cause
5.2. Study Designs to Investigate Causal Relationships
5.2.1. Cohort Study Design
5.2.2. Case-Control Study Design
5.2.3. Complicating Factors
6. Experimental Epidemiology: The Randomized Trial
7. Epidemiology for Health Systems: Use in Policy, Planning, and Assessment
8. The Future of Epidemiology
1. Introduction
1.1. Different Perspectives on Health
1.2. Different Approaches to Health Status Assessment
1.3. The Multi-Dimensional Nature of Health and Morbidity
2. A Reference Framework to Health-Related Indicators
2.1. The Bio-Medical Approach
2.2. The Functional Approach
2.3. The Perceptual Approach
2.4. The Specificity of the Dimension of Mental Health
3. From Conceptual Framework to Indicators - Health State Expectancies
3.1. A General Model of Health Transitions
3.2. Extending the General Model to Different Health Concepts
3.3. Further Characteristics of Health State Expectancies
4. Conclusion
1. Introduction
2. Evolution of Surveillance
2.1. Historical Trends
2.2. Modern Concepts
3. Definition, Purpose, and Objective of Surveillance
4. Elements of Surveillance
5. Organizations and Functions of Surveillance Systems
6. Surveillance and Research
7. Emerging Disease Threats and International Surveillance
1. Introduction
2. Family, Families
3. Family as a Life-Support System
3.1. Family Life Cycle
3.2. Reproductive Function
3.3. Productive Function
3.4. Other Functions
3.5. Gender Roles
1. Introduction
2. The Social and Economic Cost of Mental Illness
3. Classification and Diagnosis of Mental Disorders
4. The Symptoms and Sequelae of Mental Illness
4.1. Symptoms
4.2. Impairment, Disability, and Handicap Associated with Mental Illness
5. Epidemiology of Mental Disorders
5.1. Prevalence, Incidence, and Lifetime Risk
5.2. Cultural and Temporal Variation
6. The Multifactorial Causation of Mental Disorders
6.1. Genetic Vulnerability and Gene–Environment Interactions
6.2. The Complexity of Brain Structure and Function
7. Common Psychosocial Risk Factors
7.1. Gender and Mental Health
7.2. Poverty and Deprivation
7.3. Social Change and Mental Health
7.4. Migration
8. Treatment and Prevention of Mental Disorders
8.1. Treatment
8.2. Management of Psychiatric Disorders within Primary Health Care
8.3. Prevention
8.4. Rehabilitation
8.5. Countering the Stigma of Mental Illness
1. Introduction
2. Infectious Diseases Causing High Mortality
2.1. Acute Respiratory Infections
2.1.1. Pneumonia
2.1.2. Influenza
2.2. HIV/AIDS
2.3. Diarrheal Diseases
2.4. Cholera
2.5. Escherichia coli O157:H7
2.6. Rotavirus
2.7. Salmonella
2.8. Malaria
2.9. Measles
2.10. Neonatal Tetanus
2.11. Tuberculosis
3. Infectious Diseases Causing Disability
3.1. African Trypanosomiasis (Sleeping Sickness)
3.2. Chagas Disease (American Trypanosomiasis)
3.3. Dracunculiasis (Guinea-Worm Disease)
3.4. Leishmaniasis
3.5. Leprosy
3.6. Lymphatic Filariasis (Elephantiasis)
3.7. Onchocerciasis (River Blindness)
3.8. Pertussis (Whooping Cough)
3.9. Poliomyelitis
3.10. Schistosomiasis (Bilharziasis)
3.11. Sexually Transmitted Infections
3.12. Smallpox
3.13. Trachoma
4. Emerging and Reemerging Infections
4.1. Buruli Ulcer
4.2. Creutzfeldt-Jakob Disease
4.3. Diphtheria
4.4. Japanese Encephalitis
4.5. Legionellosis
4.6. Meningococcal Disease
4.7. Plague
4.8. Viral Hemorrhagic Fevers
4.8.1. Dengue/Dengue Hemorrhagic Fever
4.8.2. Ebola
4.8.3. Lassa Fever
4.8.4. Marburg
4.8.5. Rift Valley Fever
4.8.6. Yellow Fever
4.8.7. Sine Nombre/Hendra/Nipah
4.9. Viral Hepatitis
5. Causes of the Renewed Spread of Infectious Diseases
6. Limiting the Spread and Consequences of Infectious Diseases
7. Conclusion
1. Introduction
2. Chronic Noncommunicable Diseases and World Health
2.1. Epidemiological (Health) Transition
2.2. Cardiovascular and Cerebrovascular Diseases
2.3. Cancer
2.4. Chronic Obstructive Pulmonary Diseases
2.5. Diabetes
2.6. Mental and Neurological Disorders
3. Economic and Social Implications of the Emerging Epidemics of Noncommunicable Diseases
Index 349
VOLUME VII
Quality Assurance 1
Jerzy Szczerban, Professor of Surgery, Medical University of Warsaw, Poland
1. Introduction
2. Terminology
3. Background
4. Quality Assurance in Developing Countries
5. Scope of Quality Assurance
6. Health Care Quality Parameters
7. Standards
8. Consumer Movements
9. Patient Satisfaction as an Indicator of Quality
10. Approaches to Quality Assurance
11. Utilization of Health Services
12. Research on Quality Assurance
13. Information
14. Organized Quality Assurance Systems: Managed Care
15. Contention
16. Competition
1. Introduction
2. Preventive Medicine
3. Therapeutics
4. Surgical Cure
5. Diagnostic Technologies
6. Perspectives
1. Introduction
2. The Development of Health Technology Assessment
3. Establishing effectiveness evidence
4. The Appropriate Role for Health Technology Assessment
5. Current Developments: Strategic HTA
5.1 The Comprehensive Framework
6. HTA in Decision-making: An illustrated model
6.1 Framework Dimensions
6.1.1 Identifying the Population at Risk
6.1.2 Estimating Population Impact
6.1.3 Economic Concerns
6.1.4 Social Context
6.1.5. Other Considerations
7. Looking Ahead
1. Introduction
2. Background
2.1. ABC of Basic Telematics
2.2. Definition of Health Telematics
2.3. Origins of Health Telematics
2.4. Role of Health Telematics
3. Health Telematics Applications
3.1. Telecommunication
3.2. Telemedicine
3.2.1. Telematics for Relief of Professional Isolation
3.2.2. Teleconsultation
3.2.3. Telemetry and Telemonitoring
3.2.4. Telepathology
3.2.5. Teledermatology
3.2.6. Telematics for Triage
3.3. Medical Imaging
3.3.1. Image Capture and Digitization
3.3.2. Digital Diagnostic Imaging
3.3.3. Benefits of Digital Diagnostic Imaging
3.3.4. Some Types of Medical Imaging
3.3.5. Tele-imaging
3.4. Tele-education
3.4.1. Continuing Education
3.4.2. Community Health Education
4. Societal Implications of Health Telematics
4.1. Benefits
4.2. Critical Success Factors
4.3. Culture and Language
4.4. Ethics
4.5. Totalitarian Informatics
1. Introduction
2. Palliative Care . . . When to Begin?
2.1. Case I
2.2. General Prerequisites
2.3. Palliative Care at Home
2.4. Comprehensive Home Palliative Care Service
2.5. Discussion of Case I
3. Symptom Control
3.1. Case II
3.2. Pain
3.2.1. The Assessment of Pain
3.3. Discussion of Case II
3.4. Principles of Pain Management
3.5. Opioid Analgesics
3.6. Continued Discussion of Case II
3.7. Barriers to the Use of Opioids
3.8. Opioid Rotation
3.9. Asthenia
3.10. Nausea and Vomiting
3.11. Case III
3.12. Other Symptoms
4. Spiritual Suffering
5. Ethical Issues
6. Conclusion
1. Introduction
2. The Rise of Bioethics
3. The Role of (Bio)Ethics
4. Ethical Orientations
5. Duty-Based (or Deontological) Ethics
6. Consequentialist or Utilitarian Ethics
7. Other Bioethical Orientations
8. Feminist Ethics
9. (Bio)Ethical Principles
10. Respect for Persons
10.1. Autonomy of Capable Persons
10.2. Protection of Persons Incapable of Autonomy
11. Beneficence
12. Non-Maleficence
13. Justice
14. Levels of Ethical Analysis
14.1. The Microethical Level
14.2. The Macroethical Level
14.3. The Mesoethical Level
14.4. The Megaethical Level
15. Reproductive and Sexual Health Ethics
16. Research Ethics
17. Ethics and the Law
18. Ethics and Human Rights
1. Introduction
2. Biotechnology will Play a Bigger Role in our Lives
2.1. The Genetics Revolution and Human Health
2.2. Developing Ethical Guidelines for Biotechnology: Important Modern Issues to Consider
2.2.1. Involvement of Industry
2.2.2. Public Trust of Biotechnology: Engaging the Public
2.2.3. Increasing Complexity of Issues Necessitates a Global Dialogue
3. Agricultural Biotechnology
3.1. Agriculture, Food, Economics and Public Health
3.1.1. Why Some People Are Worried
3.2. The Doubly Green Revolution: Ensuring Substantial Food Security for the Poor
3.3. Transgenic Plants for the Manufacture and Delivery of Nutrients, Drugs and Vaccines
3.4. Nuffield Council on Bioethics Guidelines
4. The Human Genome Project
4.1. Aims of the Human Genome Project
4.2. Concerns Regarding the Human Genome Project and Other Genetics Research
4.3. Ethical, Legal and Social Implications (ELSI) of the Human Genome Project
4.4. The Ethical, Legal and Social Implications (ELSI) Committee of the Human Genome
Organization
4.4.1. HUGO Statement on Benefit-Sharing
5. Cloning
1. Introduction
2. Codification and Professionalism
3. Codes, Guidelines and Pre-Existing Practice
4. Medical and Related Codes of Conduct
5. The Scope of Codes and Guidelines
6. Law and Legal Enforcement
7. Ethical Interpretation and Application
1. History
2. Essential Information for Patients and Research Subjects
2.1. Extent of Disclosure
2.2. Beneficient Deception
3. Exceptions to Consent
3.1. Emergency Exception
3.2. Waiver Exception
3.3. The Therapeutic Privilege Exception
3.4. Other Exceptions
4. Patient Competence to Consent
5. Informed Consent in the Clinical Setting
6. Informed Consent in Biomedical Research involving Human Subjects
7. Obtaining Informed Consent of Subjects
7.1. Essential Information
7.2. Inducements to Participate
7.2.1. Deception and Lying
8. Research Involving Children and Other Incompetent Subjects
9. Consent to Epidemiological and Other Studies with Community Involvement
9.1. Exceptions to Consent
10. Consent in Externally Sponsored Research
11. Factors Which Nullify Informed Consent
12. Future of Informed Consent
1. Introduction
2. Definitions and Concepts
2.1. Ethics
2.2. Equity
2.3. Human Rights and Human Dignity
3. Ethics and Major Determinants of Health
3.1. Political system
3.2. Economic factors
3.3. Demographic Changes
3.4. Cultural Diversity
3.5. Global Ecosystem Sustainability
3.6. Technological advances
3.7. Changing pattern of disease
4. Future oriented approach
1. Introduction
1.1. A State of Health
1.2. New Interactions
1.3. A Context for This Article
2. The World Order
2.1. Global Village
2.2. Politicization and Corruption
2.3. Demographic Transitions and Multiple Disease Burdens
2.4. Climate and Environment
3. New Microbial Threats, the Environment in Which They Develop, and Related Matters
3.1. Germs
3.2. Mutations
3.3. New Diseases, Lifestyle, Crime
3.3.1. Human Immune-Deficiency Virus, Drugs
3.4. Environments
3.4.1. Hospital Ward Bacteria and Bacterial Resistance
3.4.2. Antibiotic Promiscuity
3.5. Nutrition
3.6. Eradicated Diseases
3.7. Low-Dose Exposure
3.8. Zoonoses
3.9. Travel Spread
3.10. Lifestyle
3.11. Vector Resistance
3.12. Agrochemical Resistance
3.13. Coordination
4. Food Chain Alterations
4.1. New Field?
4.2. Radiation
4.3. Animal Feed
4.4. Processing
4.5. Agrochemical
4.6. Packing Material
4.7. Overall Effect
5. Environmental Toxins
16.4. Labor
16.5. Patents
17. Genetically Modified Foods
17.1. Biotechnology is the Understanding and Use for Life, of the “I.T.” of Life Itself
17.2. The Right to Food, Health, Housing, and Development
17.3. The Right to a Return on Investment for Developers
17.4. Basic Ethical Considerations in Health
17.5. Biotechnology in War
17.6. Food Safety
17.7. Sustainabilty and the Environment
17.8. Marketing and Labeling
17.9. Technology Transfer, or Transfer of the Product?
17.10. Urbanization—A New Threat in Itself
17.11. Food Security
17.12. Drugs, Hormones, and Vaccines
17.13. Overview of Genetically Modified Foods
18. Conclusion
1. The Elderly
2. Aging Societies
3. Implications for Health
3.1. Equity
3.2. Social Support
3.3. Healthy Environment
3.4. Primary Health Care
3.5. Acute Hospital Care
3.6. Rehabilitation Services
3.7. Long-Term Care
3.8. Information Systems
3.9. Organizational Reform
3.10. Research
3.11. Training
3.12. Effectiveness and Costs
4. The Adaptation of Society
1. Urban Development
1.1. Increase of Urban Population
1.2. Size of Cities
1.3. Growth of Slums
2. Health Implications of Urban Growth
2.1. Urban Characteristics of Health
2.1.1. Urban Health Hazards
2.1.2. The Health Transition
2.2. Specific Health Situations in Slum Areas
3. Future Challenges
3.1. Sustainability of Urban Systems
3.2. Aging of Urban Populations
1. Introduction
2. The Context of Atmospheric and Climate Change
3. Stratospheric Ozone Depletion
4. Biological and Human Health Impact of Increased Ultraviolet Radiation Flux
5. Greenhouse Gases and Global Climate Change
6. Effects of Climate Change on Health
7. Public Health Action
8. Conclusion
1. Definitions
2. Current and Continuing Concerns of Health and Development in Border Areas
2.1. The universal neglect and marginalization of border areas, border communities and border
crossers impact communities beyond the borders.
2.2. Borders are crucial entry points for communicable diseases which, if not properly managed,
would affect the country’s population significantly.
2.3. Border communities frequently suffer from lack of health care, minimal or non-existent access
to preventive health services, emergency medical services, and health promotion.
2.4. Substance abuse, preventable injury, violence and behavioral health problems are prevalent at
the borders.
2.5. An abundance of refugees and migrant workers cross borders due to political and ethnic
conflicts and economic and natural disasters.
2.6. Borders are frequently threatened by environmental problems, and occupational hazards.
2.7. Women, children, and the elderly are at more risk, with less food security and more
malnutrition at the borders.
3. International Recognition of Health in Border Areas
4. Potential Promotion and Development
5. Conclusion
1. Introduction
1.1. Disasters
2. Disaster Medicine
2.1. A Brief History
2.2. The Scientific Base of Disaster Medicine
3. Disaster Epidemiology
3.1. Natural Disasters, Human-Made Disasters, Complex Disasters, Human-Conceived Disasters
4. Action against Disasters
4.1. International Aid
4.1.1. The United Nations and Intergovernmental Organizations
4.1.2. The International Red Cross
4.1.3. Nongovernmental Organizations
4.1.4. Bilateral Aid
4.1.5. Non-Emergency International Cooperation in Disasters
5. Emergency Medical Supplies
5.1. The Basic Unit
5.2. The Supplementary Unit
6. Disaster Terminology
7. Conflicts
8. Humanitarian Medicine
1. Introduction
2. Challenges to Improving Vaccination
3. Obstacles to Effective Vaccination
4. Solutions to Problems of Access and Coverage
5. Mechanisms: Cooperation Between Industrialized Nations and Developing Nations
6. Recent Initiatives—A Brighter Future?
6.1. The International Vaccine Institute
6.2. Global Alliance for Vaccines and Immunization
6.3. Millennium Vaccine Initiative
6.4. International AIDS Vaccine Initiative
6.5. Malaria Vaccine Initiative
7. Role of the World Health Organization
8. The Future
Health 329
John M. Last, University of Ottawa, Canada
1. Introduction
2. Definitions and Concepts of Health
3. Health as Dynamic Equilibrium: Ecology of Human–Pathogen Interactions
4. Historical Perspectives
5. Theories about Health
6. Determinants of Health
6.1 Physical Factors
6.2 Biological Factors
6.2.1 Ecology and Evolution of Infectious Diseases
6.3 Behavioral Factors
6.3.1 Personality
6.3.2 Lifestyle
6.3.3 Risk-taking Behavior
6.3.4 Substance Use and Abuse
6.4 Social Determinants of Health
6.4.1 Socioeconomic Factors
6.4.2 Occupation
6.4.3 Social Connections and Interactions
6.5 Cultural Factors
6.5.1 Human Values as a Determinant of Health
7. Requirements for Good Health
7.1 Safe Environment
7.2 Enhanced Immunity
7.3 Sensible Behavior
7.4 Good Nutrition
7.5 Well-born Children
7.6 Prudent Health Care
8. Health Indicators
8.1 Statistical Indicators
8.2 Notifiable and Reportable Diseases
8.3 Hospital and Other Medical Records
9. Health Services and Health-care Systems
Index 361
VOLUME VIII
Interactions of Environmental Change and Human Health 1
Neil Pearce, Massey University, Wellington, New Zealand
Anthony J. McMichael, London School of Hygiene and Tropical Medicine, United Kingdom
1. Introduction
2. The Agricultural Revolution
2.1 Health Effects
3. The Industrial Revolution
3.1 Health Effects
4. The Age of Development
4.1 Health Effects
5. The Information Technology Revolution
5.1 Health Effects
5.1.1 Population Health and the Physical Environment
5.1.2 Population Health and the Biological Environment
5.1.3 Population Health and the Socioeconomic Environment
5.1.4 Ecosystem Health
6. Discussion
1. Introduction
2. Goals of Epidemiology
3. Epidemiological Methods
4. Molecular Epidemiology
5. Limits of Molecular Epidemiology
6. Future Directions in Molecular Epidemiology
7. Conclusion
1. Background
1.1. The Approach to a Scientific Method in Clinical Medicine
1.2. How the Current Situation Developed
2. Essential Methodological Principles
3. Logical and Methodological Problems of Clinical Medicine Science
4. Suggestions to Improve Medical Scientific Methodology
4.1. Creation of an Integrative Medical Scientific Methodology
4.2. Use of a “Recombinant” Hypothesis-Discovery Support System
4.3. Use of a Modeling and Simulation Research Design Optimizer
4.4. Enhancement of Clinical Scientific Hypothesis Creativity
5. Underlying Theoretical and Philosophical Problems of Medical Science
6. Unified Methodological System for Investigation in Medicine
6.1. A Trans-methodological Model of Clinical, Basic and Health Sciences
6.2. Re-unification of Clinical Scientific Method for Practice and Research
7. Conclusions and Recommendations
1. Introduction
2. Science, Technology and Medicine
3. Science and Technology Disparities
4. Health Disparities
5. Global Costs of Health Technology
6. Avenues in Technological Development
6.1. Major Advances
6.2. Gene Technology and Medicines
6.3. Engineering in Medicine
7. Conclusion
1. Introduction
2. History of Surveillance
3. Background on the Modern Concept of Surveillance
3.1 The Case Definition
3.2 Data Collection
3.3 Data Management and Analysis
3.4 Data Dissemination
3.5 Evaluation of Surveillance Systems
4. Source of Surveillance Information
4.1 The Patient Treatment Record
4.2 The Population Survey
4.3 Networks for Outbreak Detection and Reporting
5. Conclusion
1. Introduction
2. Hazards and Risks Perception
3. Faring Classical Hazards
3.1 Water
3.1.1 Water Resources
3.1.2 Drinking Water
3.2 Air
3.2.1 Air Pollution
3.2.2 Indoor Air Pollution
3.3 Toxic Chemicals and Hazardous Waste Disposal
3.4 Noise
4. Emerging Risks and Global Environmental Change
5. Conclusion
1. Introduction
2. The Historical Context
2.1. In Ancient Times and Traditional Societies
2.2. MCH in an Era of Scientific Discovery and Social Concerns
3. The Elements and Technologies of MCH
4. Indicators and Information Systems for Maternal and Child Health
5. The Organization and Management of MCH Services
6. Setting Policies for MCH and the Health of Women, Children and Families
7. Conclusion: The Challenges for the Future
1. Introduction
2. Public Health
2.1. From Mythology to Modernity
2.2. Definitions and Charters
3. Ethics
3.1. How should we act?
3.2. Bioethics
3.3. International Guidelines and Codes
4. From Bioethics to Public Health Ethics
4.1. Convergences
4.2. Turning Points
4.3. Towards Codification
5. Current Challenges
5.1. Equal Rights, Unequal Needs and Access
5.2. Cultural Diversity
5.3. The North-South Ethical Gap
5.4. Efficiency vs. Ethics
5.5. Information and Communication
5.6. Precautionary Principle
5.7. Ethical Issues in day-to-day Public Health Work
6. Ethics for Public Health Tomorrow
1. Introduction
2. Topical Highlights
2.1. Health Disparities, as a Reflection of Globalization and Fragmentation of the Contemporary
World
2.2. The Geography of Health Care Systems
2.3. Environmental Change and Vector-Borne Diseases: The Contribution of Remote Sensing and
Spatial Analyses.
2.4. Bio-Environmental Correlates of Chagas’ Disease.
3. Concept Evolution
4. Urbanization and Health
5. Ageing
6. Development and Health
7. Migration
8. Concluding remarks
1. Introduction
2. Defining a Health Care System
3. Access to Health Care Services
4. Restructuring Health Care Systems
5. New Spaces of Health Care Delivery
6. Conclusions
1. Introduction
2. Undeniable convergence
2.1. « Unheard-of » statistics in mankind’s history.
2.2. A worldwide struggle
3. Increased globalisation of health needs
3.1. The threat of new infectious pandemics.
3.2. Worldwide epidemic of non-infectious diseases.
4. But a powerful dynamic of divergence
4.1. Gender-based disparities.
4.2. Appearance of extreme disparities between nations.
5. The singular case of sub-Saharan Africa.
6. The rise of a global underprivileged class.
6.1. A fall in extreme poverty but a rise in inequalities.
6.2. Socio-territorial health disparities.
7. Conclusion
Environmental Change And Vector-Borne Diseases: The Contribution Of Remote Sensing 231
And Spatial Analyses
Sophie O. Vanwambeke and Eric F. Lambin, Department of Geography, Université catholique de
Louvain, Belgium
1. Introduction
2. Biological Members and Transmission Dynamics of Disease
3. Interconnection of Wild, Peridomestic and Domestic Cycles
4. Dynamics of domiciliation of the vectors: origin and diffusion of the disease
5. The Rural Housing as Environmental Problem
6. Bioclimatic Factors of Triatominae Species
7. Description of Disease
8. Rates of Human Infection
9. Conclusions
1. Introduction
2. Epidemiology of Congenital Heart Disease
3. Types of Adult Patients with CHD
4. Congenital Heart Disease in Adults – Unoperated Survival
4.1. Common Defects with Expected Adult Survival
4.2. Common Defects with Exceptional Adult Survival
4.3. Uncommon Defects with Expected Adult Survival
4.4. Uncommon Defects with Exceptional Adult Survival
5. Why do we need Specialized Centers for the Care of Adults with CHD?
6. Transfer from Pediatric to Adult Services:
7. Organization of Services and Care
8. Conclusions
1. Introduction
2. Diagnostic Tests in Gastroenterology
3. Upper Gastrointestinal Diseases
3.1. Gastro-esophageal Reflux Disease (GERD)
3.1.1. Complications of GERD
3.2. Gastric Cancer
3.3. Peptic Ulcers and Their Complications
3.4. Dyspepsia
4. Diseases of the Intestines
4.1. Acute Infectious Diarrhea
4.2. Celiac Disease
4.3. Irritable Bowel Syndrome
4.4. Lower Gastrointestinal Bleeding
4.5. Inflammatory Bowel Disease (IBD)
4.5.1. Treatment of IBD
1. Definition of Obstetrics
2. History of Obstetrics
3. Infectious Diseases in the Pregnant Woman
4. Normal Pregnancy
5. Pregnancy Complications
5.1 Maternal Complications
5.2 Fetal Complications
6. Delivery
7. What is Gynecology
8. History of Gynecology
9. The Vulva
10. The Vagina
11. The Uterus
Index 353
VOLUME IX
Probiotic A Novel Approach To Treating Childhood Atopy 1
Aziz Koleilat , Department, Makassed University General Hospital. Riad EI-Solh 110722 10. Beirut –
Lebanon
1. Introduction
2. Mechanisms of action of Probiotic
3. The aims of intervention
4. Clinical Context
5. How Probiotics Work?
6. Probiotics & Atopy
6.1. Causes, Prevention and Treatment
6.2. Who is at risk?
6.3. The relationship between food allergy and atopic dermatitis
6.4. Strategies for a primary prevention of atopy
6.5. Use of Probiotics in Atopic Diseases
7. Conclusions
1. Introduction
1.1 Pathology coverage
1.1.1 Etiology and Pathogenesis of a Disease
1.1.2 Manifestations of Disease (Lesions)
1.1.3 Phases Of A Disease Process (Course)
1.2 Physician’s approach to patient
1.3 Types of pathologists and affiliated specialties
1.4 Role of pathologist
2. Pathology and its related disciplines
2.1 Cytology
2.1.1 Cytology Samples
2.1.2 Technical Aspects
2.1.3 Examination of Sample and Diagnosis
3. Pathology techniques and ancillary diagnostic methods
3.1 Macroscopic pathology
3.2 Light Microscopy
3.3 Polarizing light microscopy
3.4 Electron microscopy (EM)
3.5 Confocal Microscopy
3.6 Frozen section
3.7 Cyto/histochemistry
3.8 Immunocyto/histochemical methods
3.9 Molecular and genetic methods of diagnosis
3.10 Quantitative methods
4. Types of tests used in Pathology
4.1 Diagnostic tests
4.2 Quantitative tests
4.3 Prognostic tests
5. The scope of Pathology and its main divisions
6. Conclusions
1. Introduction
2. Precursor Lesions
3. Classification
3.1 Transitional Cell Carcinoma
3.2 Papillary Transitional Neoplasm of Low Malignant Potential
3.3 Papillary Transitional Carcinoma
3.4 Invasive Transitional Carcinoma
3.5 Squamous Cell Carcinoma
3.6 Adenocarcinoma
3.7 Undifferentiated Tumors
3.8 Rare Variants
4. Early detection and chemoprevention
5. Biologic features
5.1 Chromosomal Changes
5.2 Cancer Genes
5.3 P53
5.4 Mdm2
5.5 Proliferation and cell cycle markers
5.6 Ras
5.7 Other Biologic Markers
5.8 Viruses
6. Conclusion
1. Introduction
1.1 Discovery of schistosomes ( Bilharzia worms) by Theodor Bilharz
2. Life cycle of the Bilharzial parasite
2.1 Schistosomiasis species and their stages
2.2. Asexual part of life cycle (intermediate host phase)
2.3. Sexual part of the cycle
2.4. Eggs
3. Pathogenesis of Schistosomiasis
3.1. Eggs
3.2. Egg granulomas
3.3. Mechanisms underlying granuloma formation
3.4. Pathological stages of schistosomiasis
4. Clinical features of Bilharziasis due to Schistosoma mansoni infection
4.1.Skin Lesions
4.2. Acute schistosomiasis
4.2.1. Katayama fever
4.2.2. Symptoms of the acute stage
4.2.3. Treatment of Acute Phase
4.3. Intestinal Schistosomiasis (Bilharziasis); chronic stage
4.3.1. Mild and early intestinal lesions
4.3.2. Severe and prolonged cases develop specific pathological lesions which include
4.3.2.1 Bilharzial polyps
4.3.2.2. Sandy patches
4.3.2.3. Bilharzial ulcers
4.3.2.4. Intestinal fibrosis
4.4. Complications of Intestinal Bilharziasis: Includes the following
4.5. Symptoms of Intestinal Bilharziasis
4.6.Treatment of Intestinal Bilharziasis
5. Hepatosplenic Bilharziasis (Bilharzial hepatic portal fibrosis)
5.1. Pathogenesis and Pathology of Bilharzial Hepatic Fibrosis
5.1.1. The Portal Tracts show major changes
5.1.2. The Hepatic Lobules
5.1.3. Gross Features of the Affected Livers by Bilharziasis
5.2. Classification of Bilharzial Portal Fibrosis
5.2.1. Fine bilharzial periportal fibrosis
5.2.2. Coarse bilharzial periportal fibrosis
5.3. Effects of Bilharzial Portal Fibrosis and Its Complications
5.4. Causes of Death in Hepatic Bilharziasis
5.4.1. Pathogenesis of Splenic Enlargement
5.4.2. Effects and Complications of Splenomegaly
6. Bilharziasis of the urogenital system
6.1. Bilharzial Cystitis
6.2. Pathogenesis of Bilharzial Cystitis
6.3. Complications of Urinary Bilharziasis
1. Introduction
2. Types of breast lumps
3. Breast carcinoma
3.1 In Situ Carcinoma of the Mammary Gland
3.1.1 Lobular Neoplasia (LN)
3.1.2 Duct Carcinoma in Situ (DCIS)
3.2 Invasive Carcinoma of the Mammary Gland
3.2.1 Microinvasive Carcinoma of the Mammary Gland
3.2.2 Invasive Lobular Carcinoma (ILC)
3.2.3 Invasive Duct Carcinoma
3.3 Paget’s disease of the Nipple
3.4 Bilateral Breast Carcinoma
4. Conclusions
Medical Informatics and Telematics at the Threshold of the 21st Century 101
K. C. Lun, Past President, International Medical Informatics Association (IMIA) and
Professor (Adjunct), School of Biological Sciences, Nanyang Technological University, Singapore
G. W. Brauer, Associate Professor, School of Health Information Science, University of Victoria, Canada
and Member of the International Commission on the development of EOLSS Theme on Medical Sciences
1. Introduction
2. Brief History
3. Institution-centred Informatics
3.1. Hospital Information Systems
3.2. Picture Archiving and Communication Systems
4. Patient-centred Informatics
4.1. Electronic Patient / Medical Record
4.2. Knowledge Management / Decision Support
5. Community-centred Informatics
5.1. Disease Surveillance
5.2. Telehealth / Telemonitoring
6. Standards in Medical Informatics
7. Data Security, Confidentiality and Privacy in Medical Informatics
8. Medical and Health Informatics Education
8.1. Curriculum Content
8.2. Course Tracks Imbedded in non-MI Programs
8.3. Dedicated MI Programs
8.4. Modes of Delivery in MI Education
9. Promoting Medical Informatics
9.1. Professional Organizations
9.2. Conferences
9.3. Yearbook and Journals
9.4. Web Resources
9.5. Textbooks
The Past And Future Impacts Of Health/Medical Informatics On Healthcare Delivery 132
Denis J. Protti, School of Health Information Science, University of Victoria, B.C., Canada
1. Introduction
2. The Use of Computers in Health Care Is Reducing Errors and Improving Patient Safety
3. The Benefits of a Unified Electronic Health Record
4. Computer Technology in Primary Care and Chronic Disease Management
5. Using Communications Technology to Traverse Space at the Speed of Care
5.1. Tele-Semantics
5.2. Tele-Informatics in Practice
6. Conclusion
1. Introduction
2. Background
2.1. The Study of Human-Computer Interaction
2.2. Cognitive Aspects of HCI in Health Care
2.3. Human Information Processing and Distributed Cognition
2.4. Skilled Performance, Expertise and Learning
2.5. Perception and Attention
2.6. User Interaction Style
2.7. Principles for Displaying Information
2.8. Data Entry
2.9. General User Interface Principles in Health Care
3. Towards a Framework for Considering HCI in Health Care
4. Human-Computer Interaction and the System Development Life Cycle
5. Usability Engineering Methods for the Iterative Evaluation and Improvement of Health Information
Systems
5.1. Usability and Usability Testing in Health Care
5.2. Usability Inspection in Health Care
5.3. Modeling of Health Care Workflow
6. Examples of Emerging Technologies in Health Care User-Computer Interfaces
6.1. Visualization of Health Care Data
6.2. Web-based Systems
6.3. Pervasive Computing in Healthcare
6.4. Cooperative Work Environments
6.5. Customizable and Adaptive User Interfaces
7. Conclusion -- Need for Cognitive Approaches to System Design in Health Care
1. Introduction
2. Background: The Origins of Clinical Informatics
3. The Emergence of Healthcare Information Technology and the Electronic Health Record (EHR)
1. Introduction
2. Clinical Applications
3. Cell Source: All Cells are not Created Equal
4. Other Critical Issues
5. From Benchtop Research to a Product and to the Patient
6. The Future
Biomaterials 188
Eileen Gentleman, Department of Materials, Imperial College London, London SW7 2AZ, UK
Michael D. Ball, Department of Materials, Imperial College London, London SW7 2AZ, UK
Molly M. Stevens, Department of Materials, Imperial College London, London SW7 2AZ, UK
1. Introduction
1.1. History of Biomaterials
1.2. Materials in Medicine
2. Types of Materials
2.1. Metals
2.1.1. 316L Stainless Steel
2.1.2. Commercially Pure Titanium and Titanium Alloys
2.1.3. Cobalt-Chromium Alloys
2.2. Ceramics
2.2.1. Bioinert Ceramics
2.2.1.1. Pyrolytic Carbon
2.2.1.2. Alumina
2.2.1.3. Zirconia
2.2.2. Bioactive Ceramics
2.2.3. Biodegradable Ceramics
2.3. Polymers
2.3.1. Bioinert Polymers
2.3.1.1. Polyethylene (PE)
2.3.1.2. Polytetrafluorethylene (PTFE)
2.3.1.3. Polyethylene terephthalate (PET)
2.3.1.4. Polymethylmethacrylate (PMMA)
2.3.1.5. Polysiloxanes
2.3.1.6. Other
2.3.2. Bioresorbable Polymers
2.3.2.1. Hydrogels
2.3.2.2. Polyglycolic acid (PGA)
2.3.2.3. Polylactic acid (PLA)
2.3.2.4. Other
2.3.2.5. Natural Bioresorbable Polymers
3. Tissue/Biomaterials Interactions
3.1. Protein Interactions
3.2. Coagulation
3.3. Acute Inflammation
3.4. Wound Healing
3.5. Immune Responses
3.6. Foreign Body Reaction
3.7. Non-Specific Cell Responses
4. Uses of Biomaterials
4.1. Connective Tissues
4.1.1. Bone
4.1.2. Joints
4.1.3. Ligament and Tendon
4.1.4. Dental
4.1.5. Soft Tissue Repair and Augmentation
4.1.6. Sutures
4.2. Sensory Tissues
4.2.1. Nervous
4.2.2. Ocular
4.2.2.1. Contact Lenses
4.2.2.2. Artificial Vitreous Humour
4.2.2.3. Scleral Buckling Materials
4.2.2.4. Intraocular Lenses
4.2.3. Auditory
4.3. Metabolic Tissues
4.3.1. Kidney
4.3.2. Liver
4.3.3. Pancreas
4.4. Cardiovascular Tissues
4.4.1. Replacement Heart Valves
4.4.2. Cardiac Assist Devices
4.4.3. Artificial Blood Vessels
4.4.4. Stents
4.5 Drug Delivery
4.6 Tissue Engineering
5. Challenges for Biomaterials
5.1. Thrombus/Embolus
5.2. Corrosion
5.3. Wear
5.4. Infection
5.5. Calcification
5.6. Tumourigenicity
5.7. Hypersensitivity
5.8. Systemic Toxicity
5.9. Mechanical Failure
5.10. Poor Biocompatibility
6. Next Generation Biomaterials
7. Conclusions
1. Introduction
2. Limitations of Laparoscopic Surgery
3. The Development of Robotic Systems in Surgery
1. Introduction
2. Biomedical Signals and Measurement Systems
2.1. Biomedical Signals
2.2. Biomedical Instrumentation Overview
3. Physical Measurements
3.1. Flow and Volume Measurement
3.1.1. Blood Flow Measurement
3.1.2. Volume Measurement
3.2. Pressure and Force Measurement
3.2.1. Sensing Elements
3.2.2. Invasive Pressure Sensors
3.2.3. Non-invasive Pressure Measurement
3.2.4. Force Measurement
3.3. Measurement of Motion (Displacement, Velocity and Acceleration)
3.4. Chemical Measurement
3.4.1. Optically-based Sensors
3.4.2. Electrochemical Sensors
3.5. Bioelectric Measurement
3.5.1. Origin of Bioelectric Potentials
3.5.2. Biopotentials and their Applications
3.5.3. Biopotential Electrodes and Instrumentation
3.6 Measurement of Thermal Radiation
4. Conclusion
Nanobiotechnology 304
C. Ruggiero, Department of Communication Computer and System Sciences, University of Genoa, Italy
1. Introduction
2. Taxonomy and Natural History of House Dust Mites
3. Morphology of Dust Mites
4. Life Stages of Dust Mites
5. Ecology and Habits
5.1. Feeding Habits
5.2. Excretion of Faecal Pellets
5.3. Hosts
6. Effect on Health
6.1. Environmental Factors associated with Increasing Sensitivity to Mite Allergens
7. The Common Sites for House Dust Mites
8. Exposure to House Dust Mite Allergens
9. The Familiar Signs and Symptoms of Airborne Allergies
9.1. Allergic Rhinitis
9.2. Conjunctivitis
9.3. Dermatitis
9.4. Bronchial Asthma
10. Diagnosis
11. Managing Dust Mite’s Allergy
11.1. Treatment of the Patient
11.2. Modification of the Patient’s Environment
11.2.1. Furnishing
11.2.2. Floors
11.2.3. Beds
11.2.4. Stuffed Furry Toys
11.2.5. Indoor Humidity Control
11.2.6. Vacuum Cleaning
11.2.7. Air Purifiers
11.2.8. Insecticide (Acricides)
12. Conclusion
Index 339
VOLUME X
Tropical Health: A Global Challenge 1
Refaat Kamel, Ain Shams University, Egypt.
1. Introduction
2. Medical Conditions in the Tropics
2.1. Infections
2.2. Non-infectious Tropical Surgical Conditions
2.3. Emergencies in the Tropics
2.3.1. Surgical Emergencies in the Tropics
2.3.2. Obstetric Emergencies in the Tropics
3. Anaemia in Tropical Areas
4. Global Warming: The Hidden Health Risk
5. Low Cost
6. Conclusion and Hope for the Future
Food Safety – Its Role In Health And Development: The Problems Related To Our 14
Food Supply
Fritz Käferstein, International Food Safety Consultant, Nyon, Switzerland
Yasmine Motarjemi, Food Safety Manager, Néstle, S.A., Vevey, Switzerland
Gerry Moy, GEMS/Food Manager, World Health Organization, Geneva, Switzerland
1. Introduction
2. Consumer Perceptions of Risk
3. Risk and Benefit
3.1. Risk and Benefit Associated with New Food Technologies
3.2. The Negative Correlation Between Perceived Risk and Benefit
3.3. Habit
3.4. Risk Uncertainty and Variability
4. Trust in Food and Actors in the Food Chain
5. Individual Differences
6. Conclusion
The Need For An International Approach – The Role Of FAO And WHO 72
Jorgen Schlundt, Director, Department for Food Safety, Zoonoses and Foodborne diseases, World Health
Organization, Geneva, Switzerland
Kazuaki Miyagishima, Secretary, Codex Alimentarius Commission, Joint FAO/WHO Food Standards
Programme, Rome, Italy
1. Introduction
2. Food Safety Risk Assessment at the International Level
2.1. Joint FAO/WHO Expert Committee on Food Additives (JECFA)
2.2. Joint FAO/WHO Meetings on Pesticide Residues (JMPR)
2.3. Joint FAO/WHO Expert Meetings on Microbiological Risk Assessment (JEMRA)
3. Food Safety Risk Management at the International Level
3.1. Codex Alimentarius Commission (CAC)
3.1.1. Overview
3.1.2 Legal Basis and Membership
3.1.3. Organizational Structure and Strategic Planning
3.1.4. Operation and Procedure
3.1.5. International Standards and Related Texts
3.1.6. Linkage with the World Trade Organization (WTO)
3.1.7. Coordination with Other International Organizations
3.1.8. Challenges
3.2. International Food Safety Authorities Network (INFOSAN)
1. Introduction
2. Incidence and Cost of Foodborne Disease
3. Foodborne Disease Incidence Associated With the Home
4. Bacterial Contamination and the Domestic Kitchen
5. The Role of the Consumer
6. Consumer Food Preparation and Consumption Patterns
7. Mechanisms for Assessing Consumer Food Safety Behavior
8. Consumer Knowledge of Food Safety Issues
8.1. Food Storage
8.2. Cooking
8.3. Cross Contamination During Food Preparation
1. Introduction
2. Risks and Controls along the Food Supply Chain
2.1. Environmental Contamination
2.2 Raw Material (The focus of this section is on the hazards inherent to the raw material. Hazards
contaminating the raw material are addressed in the next sections.)
2.3. Primary Production
2.4. Slaughter, Harvesting, Storage and Transport
2.5. Processing and Manufacturing
2.6. Retail and Distribution
2.7. Food Preparation in Homes and in Food Service
3. Role of Food Technologies in Ensuring Food Safety
3.1. Technologies Used For Rendering Food Safe
3.1.1. Heat Treatment
3.1.2 Non-thermal Technologies
3.2. Technologies used to Control Contaminants
3.3. Technologies to Prevent Re-Contamination during or after Processing
3.4. Technologies to Support Food Analysis
3.5. Technologies to Provide Support in Logistics and Supply Chain Management
3.6. Emerging Technologies
4. Safety and Quality Assurance System
4.1. Code of Good Practices
4.2. HACCP
4.3. Verification and Validation
4.4. Traceability, Recall Procedure and Crisis Management
4.5. Management Commitment, Human Resource Management and Training
5. Challenges and Outlook
5.1. Changes Related to Internal Operations
5.2. Changes in the Environment
6. Conclusions
1. Introduction
2. Threats to Food Safety
3. Food Safety – A Shared Responsibility
4. A Role for Government
1. Introduction
2. Arterial disease
2.1. Surgery of carotid arteries
2.2. Arteries of aortic arch
2.3. Aneurysms in descending aorta.
2.4. Thoracoabdominal aneurysms.
2.5. Aneurysms of the abdominal aorta
2.6. Aneurysms of the peripheral arteries.
2.7. Surgical treatment of peripheral arterial occlusive disease (PAOD)
2.8. Acute limb ischemia
2.9. Arterial injuries
3. Venous diseases
3.1. Varicose Veins in lower limbs
3.2. Treatments of the deep vein thrombosis.
1. Introduction
2. Scope of Pediatric Surgery
3. Progress in Pediatric Surgery as a Result of New Life Saving Procedures and Technologies
4. Neonatal Surgery
4.1. Introduction
4.2. Fetal Surgery
4.2.1. Types of Fetal Surgery
4.3. FIGS Procedures
4.4. FETENDO Procedures
4.5. Open Fetal Surgery
4.6. Summary of Fetal Surgery.
4.7. ECMO as a Life Supporting System in Neonates with Respiratory Failure
4.8. Technical Aspects of ECMO
4.9. Complications of ECMO
4.10. Results of ECMO Therapy
5. Surgery in Children with Coagulopathy
6. Coagulation and Liver Diseases
6.1. Coagulopathy
6.2. Activated Recombinant Factor VII
6.3. Summary of Coagulopathy in Liver Diseases
7. Other Advances in Bleeding Control and Hemostasis in Pediatric Surgery
8. Modern Liver Support or Substitution Possibilities in Children
9. Liver Transplantation as a Life Saving Procedure in Children with Liver Failure
1. Introduction
2. Terminology
3. Liver Resection
3.1. Liver Resection Nomenclature
3.2. New Diagnostic Possibilities
3.3. Principles of Liver Resection
3.3.1. Vascular Control
3.3.2. New Surgical Devices
4. Operative Procedures
4.1. Laparoscopic Technique
4.2. Management of the Portal Hypertension
5. Treatment of the Most Common Liver Lesions
5.1. Benign Tumors
5.1.1. Cysts
5.1.1.1. Solitary Liver Cysts
5.1.1.2. Hydatoid Cysts
5.1.2. Hemangioma
5.1.3. Focal Nodular Hyperplasia
5.1.4. Adenoma
5.2. Malignant Tumors
5.2.1. Hepatocellular Carcinoma
5.2.2. Cholangiocarcinoma (Peripheral Type)
5.2.3. Secondary Tumors
1. Definition
2. Historical notes
3. Classification
3.1. From an anatomical standpoint; GI fistulas are traditionally classified as internal or external.
3.2. Classification based on the loss of fluid, electrolytes and proteins.
3.3. Classification according to etiology.
4. Etiology
4.1. Spontaneous fistulae clearly imply the presence of an underlying pathology.
4.2. Acquired fistulae.
5. Evolution of the Management of Fistulae:- The MGH Experience.
5.1. The first period
5.2. The Second period
5.3. The third period,
5.4. Preliminary concluding remarks.
6. Management of gastrointestinal fistulae.
6.1. Stabilization
6.2. Investigations
6.3. Decision
6.4. Definitive therapy.
6.5. Healing phase
7. Summary and Conclusions
1. Introduction
2. Citizen’s Participation in Subjects of Science and Technology
3. The Modalities and Methodologies of Citizen Participation in R&D Issues
4. The Citizens Consensus Conference (CCC)
1. Introduction
2. Trends in health research financing
2.1. Total funding and trends
2.2. Public sector funding
2.3. Private sector funding at the Global level
2.4. Private not-for-profit
2.5. Low- and middle-income countries
2.6. Innovative developing countries
3. Financing for research on neglected diseases
3.1. Investments in malaria research
3.2. Investments in HIV-AIDS research
3.2.1. HIV vaccine research
3.2.2. HIV Microbicide research
3.3. Comparisons of disease burden and research funding
4. Public-Private Interactions: new modalities for financing neglected disease research
4.1. Progress and concerns
5. Scientific production and financing
6. Challenges ahead
Index 331
VOLUME XI
An Introduction To Pharmacology 1
H. Majewski, School of Medical Sciences, RMIT University, Australia
1. History of Pharmacology
2. Pharmacodynamics and Receptors
3. Molecular Pharmacology
3.1. Receptors: Ligand Gated Ion Channels
3.2. Receptors: G-protein Coupled Receptors
3.3. Enzyme Linked Membrane Receptors
3.4. Nuclear Receptor Family
3.5. Ion Channels
3.6. Molecular Basis of Bacterial Chemotherapy
3.7. Molecular Basis of Viral Chemotherapy
3.8. Molecular Basis of Cancer Chemotherapy
4. Pharmacokinetics
5. Pharmacogenomics
6. Safety Pharmacology
7. Drug Discovery
8. Clinical Pharmacology
Neuropharmacology 42
Emilio Badoer, School of Medical Sciences, RMIT University, Melbourne, Victoria, Australia
1. Introduction
2. Excitatory Amino Acids
2.1. Receptors for Glutamate
2.1.1. NMDA Receptors
2.1.1.1. Physiological Effects Of NMDA Receptors
2.1.1.2. Role Of NMDA Receptors In Disease
2.1.1.3. Agonists of NMDA Receptors
2.1.1.4 Antagonists of NMDA Receptors
2.1.2. AMPA Receptors
2.1.2.1. Physiological Effects of AMPA Receptors
2.1.2.2 Role Of AMPA Receptors In Disease
2.1.2.3. Agonists of AMPA Receptors
2.1.2.4. Antagonists of AMPA Receptors
2.1.3. Kainate Receptors
2.1.3.1. Physiological Effects of Kainate Receptors
2.1.3.2. Role of Kainate Receptors in Disease
2.1.3.3. Agonists Of Kainate Receptors
2.1.3.4 Antagonists Of Kainate Receptors
2.1.4. Metabotropic Glutamate Receptors
2.1.4.1. Physiological Effects of mGluRs
2.1.4.2. Role of mGluRs in Disease
2.1.4.3. Agonists of mGluRs
2.1.4.4. Antagonists of mGluRs
3. Gamma-aminobutyric Acid (GABA)
3.1. Receptors for GABA
3.1.1. Ligand-gated Ion Channel GABA Receptors
3.1.1.1. GABAA Receptors
1. Diuretics
1.1. Introduction
1.2. Endogenous Diuretics
1.3 Diuretics
1.3.1. Nephron Structure
1.3.2. Osmotic Diuretics
1.3.3. Carbonic Anhydrase Inhibitors
1.3.4. Loop Diuretics
1.3.5. Thiazide and Thiazide-like Diuretics
1.3.6. K+-Sparing Diuretics
2. Antiplatelet, Anticoagulants and Fibrinolytic Agents
2.1. Introduction
2.2. Brief Overview of Thrombus Formation
2.3. Antiplatelet Drugs
2.3.1. Aspirin
2.3.2. Purinergic P2Y12 Receptor Antagonists
2.3.3. GPIIb/IIIa Antagonists
2.4. Anticoagulants Drugs
2.4.1. Heparin and Heparin Fragments
2.4.2. Warfarin
2.4.3. Fondaparinux
2.5. Fibrinolytic Agents
3. Drugs That Increase Blood Pressure
4. Drugs That Decrease Blood Pressure
4.1. Systemic Hypertension
4.1.1. Introduction
4.1.2. Epidemiology
4.1.3. Types of Systemic Hypertension
4.2. Treatment of Systemic Hypertension
4.2.1. Diuretics
4.2.2. β-Adrenoceptor Antagonists (β-Blockers)
4.2.3. Calcium Channel Blockers
4.2.4. Inhibitors of the Renin-Angiotensin System
4.2.5. α1-Adrenoceptor Antagonists
1. Introduction
2. Clinical Pharmacokinetics
2.1. Clearance
2.2. Volume of Distribution
2.3. Half-life
2.4. Dose Determination
2.5. ADME: Drug Absorption and Bioavailability
2.6. ADME: Drug Distribution
2.7. ADME: Drug Metabolism
2.8. ADME: Elimination
2.9. Drug Dosing in Pediatric and Geriatric Populations
3. Pharmacodynamics
4. Pharmacogenetics
5. Quality Use of Medicines
6. Therapeutic Drug Monitoring
7. Population Pharmacokinetics
8. Toxicology
9. Clinical Pharmacology and Drug Development
10. Conclusion
1. Introduction
2. Movement of Drugs in the Body
2.1. Mass Transport
2.2. Passage through Biological Membranes
3. Absorption of Drugs
3.1. Oral Administrations
3.2. Parenteral Route of Entry
3.2.1 Percutaneous
3.2.2 Nose and Eyes
3.3. Inhalation
3.4. Bioavailability
3.4.1. Physiological Factors
3.4.2. Other Properties
3.5. Therapeutic Delivery Systems (Prodrugs, Implants, etc.)
4. Distribution
4.1. Blood Brain Barrier (BBB)
4.2. Placental Distribution.
5. Elimination of Drugs
5.1. Metabolism
5.1.1. Phase I Enzymes
5.1.2. Phase II Enzymes
5.1.3. Tissue distribution of drug metabolizing enzymes
5.1.4. Enzyme Inhibition
5.1.5. Enzyme Induction
5.1.6. Genetic and other factors
5.2. Excretion
5.2.1. Factors affecting urinary excretion of drugs
5.2.2. Other routes of drug excretion
6. Mathematical parameters in pharmacokinetics
6.1. Volume of distribution
1. Introduction
2. How Do We Determine a Person’s Phenotype?
3. How Do We Determine a Person’s Genotype?
4. Nomenclature Used For Genetic Variants
5. History of Pharmacogenetics and Genomics
6. Pharmacogenetics of Drug Metabolising Enzymes and Transporters: Pharmacokinetics
6.1 Drug Metabolizing Enzymes
6.1.1 Genetic Basis of the Polymorphisms
6.1.1a. Phase I enzymes
6.1.1b. Phase II Enzymes
6.1.2. Impact of Pharmacogenetics on Drug Metabolism and Pharmacokinetics
6.1.2a. Phase I Pathways
6.1.2b. Phase II Pathways
6.2. Drug Transporters
6.2.1. Genetic Basis of the Polymorphisms
6.2.1a. ABC Efflux Transporters – ABCB1 (P-Glycoprotein)
6.2.1b. ABC Efflux Transporters – ABCC (Multidrug Resistance-Associated Proteins,
MRP)
6.2.1c. ABC Efflux Transporters – ABCG2 (Breast Cancer Resistance Protein)
6.2.1d. Uptake Transporters
6.2.2. Impact of Pharmacogenetics on Drug Distribution Pharmacokinetics
6.2.2a. ABC Efflux Transporters – ABCB1 (P-glycoprotein)
6.2.2b. ABC Efflux Transporters – ABCC (Multidrug Resistance-Associated Proteins)
6.2.2c. ABC Efflux Transporters – ABCG2 (Breast Cancer Resistance Protein)
6.2.2d. Uptake Transporters
7. Pharmacogenetics of Drug Targets: Pharmacodynamics
7.1. G-Protein Coupled Receptors
7.1.1. Beta Adrenoceptors
7.1.2. Beta 1 Adrenoceptors
7.2. Enzymes as Drug Targets
7.3. Ion Channel Drug Targets
7.4. Transporters as Drug Targets
8. Pharmacogenetics and Drug Safety
8.1. TMPT and Thiopurine Dosing
8.2. UGT1A1 Polymorphism and Irinotecan Toxicity
9. Future Directions
Neuropsychopharmacology 193
Mirjam A.F.M. Gerrits, Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and
Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
Jan M. van Ree, Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and
Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
1. Introduction
1. Introduction
1.1. Concept of Hormone Action
1.1.1. Hormone Synthesis and Secretion
1.1.2. Feedback Regulation
1.1.3. Paracrine and Autocrine Regulation
1.1.4. Hormone Rhythms and Pulsatility
1.2. Endocrine Organs
1.3 Control of Hormone Secretion
1.3.1. Morphology of Endocrine Cells
1.3.2. Composition of Mature Secretory Granules
1.3.3. Regulation of Exocytosis by Calcium
1.3.4. Modulation of Exocytosis by Protein Kinase C
2. Neuroendocrinology and Pituitary Diseases
2.1. Pharmacologic Principles
2.2. Diseases of the Pituitary
2.2.1. Pituitary Hypofunction (Hypopituitarism)
2.2.2. Pituitary Hyperfunction
2.2.3. Growth Hormone Excess (Acromegaly)
2.2.4. GH Deficiency
3. Thyroid Diseases and Disorders of Metabolic Rate
3.1. Hypothyroidism
3.2. Hyperthyroidism
4. Disorders of Carbohydrate Metabolism
4.1. Insulin Receptor and Function
4.2. Counter-Regulatory Hormones to Insulin
4.3. Diabetes Mellitus
4.4. Insulin in the Treatment of Diabetes Mellitus
4.5. Oral Hypoglycemic Drugs for Diabetes
4.6. Hypoglycemia
1. Introduction
2. Drugs that Control Gastric Acid Secretion and Treat Peptic Ulcers
2.1. Antacids
2.2. Histamine (H2) Receptor Antagonists
2.3. Proton Pump Inhibitors (PPIs)
2.4. Helicobacter pylori (H. pylori) Therapy
3. Drugs Stimulating Gastrointestinal Motility
3.1. Dopamine D2-receptor Antagonists
3.2. Serotonin 5-HT4 Receptor Agonists
3.3. Macrolides
4. Drugs to Treat Constipation
4.1. Laxatives
5. Drugs to Treat Diarrhea
5.1 Antidiarrheal Agents
6. Drugs to Treat Emesis
6.1. Antiemetic Agents
7. Drugs to Treat Irritable Bowel Syndrome (IBS)
7.1. Spasmolytics
7.2. Serotonin Compounds: 5-HT3 Receptor Antagonist and 5-HT4 Receptor Agonists
8. Drugs to Treat Inflammatory Bowel Disease (IBD)
8.1. Anti-IBD Therapies
1. Introduction
2. Categories of Poison
2.1. Physical Agents
2.2. Chemical Agents
2.2.1. Metals as Poisons
2.2.2. Alcohols - Delicious Poisons
2.2.3. Glycosides and Cyanogenic Compounds-Plant Poisons
2.2.4. Insecticides and Herbicides–Useful Poisons
2.2.5. Over the Counter Analgesics
2.2.6. Central Nervous System (CNS) Depressants
2.2.7. Drugs of Abuse
2.3. Biological Agents
2.3.1. Plant and Microbial Toxins
2.3.2. Animal Venoms and Toxins
2.3.2.1. Amphibian Toxins
2.3.2.2. Marine Toxins
2.3.2.3. Reptile Toxins
2.3.2.4. Arthropod Toxins
3. Toxins in Therapy
3.1. Animal Toxins in Therapy
1. Introduction
2. Drug Screening Studies for Assessing Pharmacological Activity
3. Safety Pharmacology Studies in the Context of Regulatory Guidelines
4. Use of in vitro Systems and in vivo Models for Safety Pharmacology Testing
4.1. Core Battery Studies
4.1.1. Cardiovascular System
4.1.2. Respiratory System
4.1.3. Central Nervous System
4.2. Supplemental Studies
4.2.1. Renal/Urinary System
4.2.2. Gastro-intestinal System
4.2.3. Autonomic Nervous System
4.2.4. Immune System
4.2.5. Dependency Potential
4.2.6. Effects on Skeletal Muscle
4.2.7. Endocrine System
5. Concluding Remarks
1. Introduction
2. Pharmacological Receptors
3. What is Pharmacodynamics?
4. Definitions of Pharmacological Terms
5. Affinities
5.1. Micro- and Macro-Affinity
6. Efficacy
7. The Operational Model for Agonism
8. Drug Antagonism
8.1. Orthosteric Antagonism
8.2. Allosteric Modulation
9. Partial Agonism
10. Inverse Agonism
11. Data-Driven Pharmacodynamics in Drug Discovery
11.1. Agonists
11.2. Antagonists
12. Conclusions
Index 355
VOLUME XII
The Autonomic Nervous System 1
James Ziogas, Department of Pharmacology, University of Melbourne, Parkville Victoria, 3010,
Australia.
Fred Mitchelson, Department of Pharmacology, University of Melbourne, Parkville Victoria, 3010,
Australia.
1. Introduction
2. Anatomical and Functional Organization of the Efferent Peripheral Nervous Systems
2.1. Somatic and Autonomic Nerves
3. Sympathetic and Parasympathetic Divisions of the Autonomic Nervous System
3.1. Anatomical considerations
3.2. Physiological considerations
3.3. Pharmacological and Biochemical considerations
4. Noradrenergic transmission
4.1. Synthesis
4.2. Storage
4.3. Release
4.4. Inactivation
4.4.1. Neuronal Uptake
4.4.2. Extra-neuronal Uptake
4.4.3. Metabolism
4.5. Receptors for Noradrenaline
4.5.1. Adrenoceptor Structure and Signaling
4.5.2. Targeting α-adrenoceptors
4.5.3. Targeting β-adrenoceptors
5. Cholinergic Transmission
5.1. Synthesis
5.2. Storage
5.3. Release
5.4. Inactivation
5.4.1. Cholinesterase inhibitors
5.4.2. Targeting Acetylcholinesterase
5.5. Receptors for Acetylcholine
5.5.1. Nicotinic Cholinoceptors
5.5.2. Muscarinic Cholinoceptors
5.5.3. Targeting Nicotinic Cholinoceptors
5.5.4. Targeting Muscarinic Cholinoceptors
5.5.4.1 Agonists
5.5.4.2 Naturally occurring muscarinic agonists
5.5.4.3 Synthetic muscarinic agonists
5.5.4.4 Muscarinic cholinoceptor antagonists
5.5.4.5 Allosteric modulators and allosteric agonists
6. Conclusion
1. Introduction
2. Neuromuscular transmission and contraction in skeletal muscle
2.1. Safety factor in transmission
2.2. Train of four and tetanic stimulation
2.3. Twitch, tetanic contraction and tremor
3. Neuromuscular blocking drugs
4. Non-depolarizing neuromuscular blocking drugs
1. Introduction
2. The Major Mediators of Inflammation and their Origins
2.1. Histamine and other Vasoactive Amines
2.2. Kinins
2.3. Complement
2.4. Clotting Factor Cascade – Thrombin and Activated Protein C (APC)
2.5. Arachidonic Acid (AA) Metabolites and Platelet Activating Factor
2.5.1. Cyclo-oxygenases
2.5.2. Production and Degradation of Prostanoids
2.5.3. Prostaglandin E2 (PGE2)
2.5.4. Prostaglandin D2 (PGD2)
2.5.5. Prostaglandin F2α (PGF2α)
2.5.6. Prostacyclin (PGI2)
2.5.7. Thromboxane A2
2.5.8. Therapeutic exploitation of prostanoids and their receptors
2.5.9.5-lipoxygenase (5LO)
2.5.10. Cysteinyl Leukotrienes (Cys-LTs)
1. Introduction
2. Reproductive Glands and Hormones and Their Regulation
2.1. The Hypothalamic Factor
2.2. The Pituitary Hormones
2.3. The Gonadal Hormones
2.3.1. Androgens
2.3.2. The Female Sex Steroids
2.3.3. Gonadal Peptides
2.4. Prostanoids
2.5. Steroid Hormone Receptors And Drugs Targeting Them
2.5.1. The Androgen Receptor
2.5.2. Estrogen Receptors
2.5.3. Progesterone Receptors
3. Testicular Function and its Control
4. The Menstrual Cycle and Drugs used in Menstrual Disorders and the Menopause
4.1. The Menstrual Cycle
4.1.1. Ovarian Events
4.1.2. Uterine Events
4.1.3. Hormonal Control of the Menstrual Cycle
4.1.4. The Menstrual Cycle During the Lifespan
4.2. Menstrual Cycle Disorders and Their Treatment
4.2.1. Amenorrhea
4.2.2. Polycystic Ovarian Syndrome (PCOS)
4.2.3. Menorrhagia
4.2.4. Dysmenorrhea
4.2.5 .Endometriosis
4.3. Management of the Menopause and Disorders Associated with the Menopause with Hormonal
Products (HRT)
5. Fertility and Conception
5.1. Hormonal Contraception
5.1.1. The Combined Oral Contraceptive Pill
5.1.2. Progestogen-only Methods of Contraception
5.1.3. Hormonal Contraception for Men
5.2. Drugs used in Erectile Dysfunction
5.3. Management of Infertility
6. Pregnancy and Parturition, Lactation and Pharmacological Interventions
6.1. Drug Treatments in Pregnancy
6.2. Induction of Labor
6.3. Pain Relief in Labor
6.4. Management of Third Stage of Labor
6.5. Drugs used in Premature Labor
6.6. Drugs Modifying Lactation
7. Environmental and Other Non-therapeutic Agents Affecting Reproduction and Development
7.1. Exposure to EDs
7.2. Mechanism of Action
7.3. Effects of EDs
7.4. Do Xenoestrogens and Other EDs Pose a Risk to Human Health?
7.5. Examples of Potential EDs
7.5.1. Phytoestrogens
7.5.2. Phthalates
7.5.3. Vinclozolin
8. Conclusion
Anesthetics 269
Amanda Baric, Department of Anesthesia and Perioperative medicine, The Northern Hospital,
Melbourne, Australia.
David Pescod, Department of Anesthesia and Perioperative medicine, The Northern Hospital, Melbourne,
Australia.
1. Inhalation Agents
1.1. Introduction
1. Introduction
2. Relation of Gene Therapy to Other Biotechnologies
3. Gene Therapy Technologies
3.1. Classification of Gene Therapy Techniques
3.2. Physical Methods of Gene Transfer
3.2.1. Electroporation
3.2.2. Particle Bombardment
3.2.3. Ultrasound-mediated Transfection
3.2.4. Molecular Vibration
3.2.5. Gene Transfection using Laser Irradiation
3.2.6. Photochemical Transfection
3.2.7. Chemical Methods of Gene Transfer
3.3. Ex vivo and In vivo Gene Therapy
3.3.1. Ex vivo Gene Therapy
3.3.2. In vivo Gene Therapy
3.4. Gene Repair and Replacement
3.4.1. Gene Repair by Single-stranded Oligonucleotides
3.5. Spliceosome-mediated RNA Trans-splicing
3.6. Vectors for Gene Therapy
3.6.1. Use of Genes as Pharmaceuticals
3.6.2. The Ideal Vector for Gene Therapy
3.6.3. Viral Vectors
3.6.4. Non-viral Vectors for Gene Therapy
3.7. Concluding Remarks about Vectors
3.8. Cell-mediated Gene Therapy
3.8.1. Stem Cell Gene Therapy
3.9. Routes of Administration for Gene Therapy
3.10. Targeted Gene Therapy
3.10.1. Controlled Induction of Gene Expression
3.10.2. Controlled Gene Therapy
3.10.3. Technologies for Gene Suppression
3.10.4. Locked Nucleic Acid
Index 359
VOLUME XIII
Ethnopharmacology: An Overview 1
Elaine Elisabetsky, Laboratory of Ethnopharmacology, Universidade Federal do Rio Grande do Sul,
Porto Alegre, Brazil.
Nina L. Etkin, Departments of Anthropology and Ecology & Health, University of Hawai'I, USA.
1. Introduction
1.1. Defining Ethnopharmacology
2. Methods
3. Contexts of Medicinal Plant Use
3.1. The Social Relations of Healing
3.2. Criteria Used in the Selection of Plant Medicines
3.3. Preparation of Plant Medicines
3.4. Interactions among Plants and between Plants and Pharmaceuticals
3.5. Outcome and Efficacy
3.5.1 Do Medicines Work?
3.5.2 How do Medicines Work?
3.5.3 Efficacy versus effectiveness
4. Multicontextual Plant Use
1. Introduction
2. Primates, Birds, and Butterflies
3. Shanidar
4. Ötzi
5. Herbals
6. Native American Medicinal Plants
6.1. St. John’s Wort, Hypericum hypericoides Crantz (Clusiaceae)
6.2. Yarrow, Achillea millefolium L. (Asteraceae)
6.3. Crane’s-bill or Wild Geranium, Geranium maculatum.L. (Geraniaceae)
7. Conclusions
1. Introduction
2. Approaches for the discovery of new drugs from higher plants
3. Selection of plant material
4. Biological and pharmacological targets
5. Chemical screening
5.1. Metabolite profiling: a LC-multi-hyphenated strategy
5.2. Problems encountered in metabolite profiling
5.3. Application of LC/UV/MS and LC/NMR in phytochemical analysis
5.3.1. Dereplication of flavanones and isoflavones in crude plant extracts
5.3.1.1. Dereplication of the antifungal constituents of Erythrina vogelii by LC/UV/MS and
on-flow LC/1H-NMR.
5.3.1.1.1 High resolution LC/UV/APCI-Q-TOF/MS/MS analyses
5.3.1.1.2. Low-flow LC/1H-NMR with microfractionation
5.3.1.1.3. LC/UV-DAD with post-column derivatisation
5.3.1.1.4. De novo structure determination based on on-line data
5.3.2. Stop-flow LC/1H-NMR with 2D correlation experiments for the structure elucidation of a
flavanone of Monotes englerii
5.4. Combination of LC/NMR and LC/MS with in-mixture NMR experiments for the investigation
of labile constituents
5.4.1. On-line characterisation of unstable cinnamic ester derivatives in Jamesbrittenia fodina
5.4.2. Study of epimerisation reactions
5.5. On-line absolute configuration determination
6. Isolation of active principles and their structure determination
7. Conclusion
1. Introduction
2. Anthropological (Ethnographic) Field Methods
2.1. Informed Consent and Research Ethics
2.2. Identifying/Inviting Study Participants
2.3. Key Respondents/Informants
2.4. Participant Observation
2.5. Semi- and Unstructured Interviews and Questionnaires
2.5.1. Unstructured Interviews
2.5.2. Semi-Structured Interviews
2.5.3. Frame Elicitation
2.5.4. Cultural Domain Analysis
2.5.5. Free-Listing
2.5.6. Pile Sorts
2.5.7. Triad Exercise
2.5.8. Questionnaires
2.6. Discourse, Narrative, and Text Analysis
2.7. Group Interview Methods
2.7.1. Community Interviews
2.7.2. Natural Group
2.7.3. Consensus Panel
2.7.4. Focus Group
2.8. Quantitative Data
2.9. Prioritizing (Ethnographic) Methods
3. Integrating Ethnographic and Ecological Field Methods
3.1. Ecocultural Research Questions in Ethnopharmacology
3.2. Examining Ecological Factors that Influence the Collection of Medicinal Plants
3.3. Distinguishing Environmental Versus Genetic Variation
3.4. Assessing Relationships between Anthropogenic Landscape Changes and Medicinal Plants
3.5. Ecocultural Research on Medicinal Plant Conservation
3.6. Variation in Plant Collection and Management Methods
3.7. Assessing the Ecological Impacts of Variation in Plant Collection
3.8. Participatory Ecological Research Methods Applied to Medicinal Ethnobotany
3.9. Assessing the Ecological Consequences of Medicinal Plant Harvest on Other Organisms
4. Conclusion
1. Introduction
2. Historical Trends
3. Present Trends
3.1. Ethnopharmacological Databases
3.2. New Models for Ethnopharmacological Databases
3.3 Managing Field Data and Workflow
3.4 Voucher Specimens and Ethnopharmacological data
4. Conclusions and Future Challenges
1. Introduction
2. What are Professional Ethics?
2.1. Ethnopharmacology as a Profession
2.2. Unearthing a Professional Ethic for Ethnopharmacology
3. External Standards for Ethnopharmacology
3.1. Approvals
3.2. Permissions and Permits
3.2.1 Documentation of Cultural Knowledge
3.2.2 Genetic Resources
3.3. Compensation and Benefit-sharing
3.4. Credit and Rights Issues
3.5. Community Protocols
4. Remaining Challenges for Ethnopharmacology as a Profession
5. Conclusions
1. Introduction
2. Medicinal plants in the evolution of biomedicine
2.1. Medicinal plants as landmarks in medical history
2.1.1. Ancient times
2.1.2. Arabic and Greek legacies
2.1.3. Last century of the second millennium legacy
2.2. Medicinal plants as sources of prototypic agents
3. Disease Control in a cross-cultural context: a case of applied ethnopharmacology to common intestinal
parasitism.
3.1. Knowledge accumulated by American peoples in the treatment of worms
3.2. Ethnopharmacology applied to intestinal worms. A Cost-effectiveness study for community
control of ascariasis comparing herbal and pharmaceutical treatments in Ecuador
4. Material and Methods
4.1. Study design
4.2. Study Subjects
4.3. Effectiveness assessment
5. Results and analysis
5.1. Population’s living conditions
5.2. Prevalence of parasitism
5.3. Risk factors of Ascariasis: association between ascariasis and selected explanatory variables.
5.4. Regression Analysis
5.5. Analysis of risk factors
5.6. Treatment groups
5.7. Evaluation of effectiveness of treatments
5.8. Cost/effectiveness analysis
6. Discussion: Health, sustainable development and socio-economic aspects of treating the most common
parasitic disease in the world
6.1. Multidisciplinary approach
6.2. Importance of ecological preservation and human security
6.3. Limitations of this study
7. Recommendations for further research:
8. Policy implications
1. Introduction
2. Plant-Derived Anti-Cancer Agents in Clinical Use
3. Plant-Derived Anticancer Agents in Clinical Development (Figure 2)
4. Targeting Natural Products
5. Plant-Derived Antitumor Agents in Preclinical Development (see Figure 3)
6. Cell Cycle Target Inhibition and Anticancer Drug Discovery
7. Conclusions
Traditional Medicinal Plants For The Treatment And Prevention Of Human 196
Parasitic Diseases
Merlin L Willcox, Research Initiative on Traditional Antimalarial Methods, Buckingham, UK
Benjamin Gilbert, FarManguinhos-FIOCRUZ, Rua Sizenando Nabuco, Rio de Janeiro, Brazil.
1. Introduction
2. Protozoa
2.1. Blood protozoa
2.1.1 Malaria
2.1.1.1 Importance of traditional medicine in treatment of malaria
2.1.1.2 Important plant species and their active ingredients
2.1.1.2.1 Ethnobotanical studies
2.1.1.2.2 Pharmacological studies
2.1.1.2.3 Clinical safety and efficacy
2.1.1.3 Vector control
2.1.1.3.1 Mosquito Repellents
2.1.1.3.2 Larvicides
2.1.1.4 Future Directions for Research
2.1.2 Trypanosomiasis
2.1.2.1 Human African Trypanosomiasis (sleeping sickness)
2.1.2.1.1 The importance of traditional medicine for African trypanosomiasis
2.1.2.1.2 Important plant species and their active ingredients
2.1.2.1.3 Clinical safety and efficacy
2.1.2.2 American Trypanosomiasis (Chagas’ disease)
2.1.2.2.1 Important plant species and their active ingredients
2.1.2.2.2 Vector control
2.2. Tissue protozoa
2.2.1 Leishmaniasis
2.2.1.1 The importance of traditional medicine for cutaneous leishmaniasis
2.2.1.2 The importance of traditional medicine for visceral leishmaniasis
2.2.1.3 Important plant species and their active ingredients
2.2.1.4 Clinical safety and efficacy
2.2.1.5 Vector control
2.3. Intestinal protozoa
2.3.1. Importance of Traditional Medicine
2.3.2. Important plant species and active ingredients
3. Helminths (worms)
3.1. Nematodes (roundworms)
3.1.1. Intestinal nematodes
3.1.1.1 Importance of traditional medicine
3.1.1.2 Important plant species and active ingredients
3.1.1.3 Clinical safety and efficacy
3.1.2 Blood nematodes
Index 225
VOLUME XIV
Plants And Plant Substances Against AIDS And Other Viral Diseases 1
P. Cos, L. Maes, Laboratory for Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical,
Biomedical and Veterinary Sciences, University of Antwerp, Belgium
D. Vanden Berghe, Laboratory for Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical,
Biomedical and Veterinary Sciences, University of Antwerp, Belgium
N. Hermans, Laboratory of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical, Biomedical
and Veterinary Sciences, University of Antwerp, Belgium
S. Apers, Laboratory of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical, Biomedical and
Veterinary Sciences, University of Antwerp, Belgium
A.J. Vlietinck, Laboratory of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical,
Biomedical and Veterinary Sciences, University of Antwerp, Belgium
1. Introduction
2. The plant kingdom as source of new antiviral agents
2.1. Opportunities and challenges
2.2. Selection of plants
2.3. Preparation of plant extracts
3. Antiviral test methodology
4. Plant-derived anti-Human Immunodeficiency Virus (anti-HIV) agents
4.1. AIDS and anti-HIV drugs
4.2. AIDS and traditional medicine
4.3. Plant-derived anti-HIV agents
4.3.1. Alkaloids
4.3.2. Carbohydrates
4.3.3. Coumarins
4.3.4. Flavonoids
4.3.5. Lignans
4.3.6. Naphthodiantrones
4.3.7. Phenolics
4.3.8. Phorbol esters
4.3.9. Proteins
4.3.10. Tannins
4.3.11. Terpenes
5. Plant-derived anti-Herpes Simplex Virus (anti-HSV) and anti-cytomegalovirus (anti-CMV) agents
5.1. The human herpes virus (HHV) family and anti-HHV drugs
5.2. Plant-derived anti-HSV and anti-CMV agents
5.2.1. Alkaloids
5.2.2. Carbohydrates
5.2.3. Flavonoids
5.2.4. Lignans
5.2.5. Phenolics
5.2.6. Proteins
5.2.7. Tannins
5.2.8. Terpenes
5.2.9. n-Docosanol
6. Plant-derived anti-influenza virus agents
6.1. Influenza and anti-influenza drugs
6.2. Plant-derived anti-influenza virus agents
7. Conclusions
1. Introduction
2. Principal plants that have contributed to the development of modern analgesic and anti-inflammatory
drugs
2.1. Papaver somniferum
2.2. Salix species
2.3. Cannabis sativa
2.4. Capsicum sp.
2.5. Panax ginseng
2.6. Tanacetum parthenium
2.7. Aconitum sp.
3. New plant-derived substances with potential antinociceptive or anti-inflammatory properties
3.1 Siphocampylus verticillatus
3.2 Drymis winteri
3.3 Hedyosmum brasiliense
3.4. Phyllanthus sp.
3.5. Protium sp.
4. Possible biological targets for botanical-derived substances with potential anti-inflammatory and
antinociceptive properties
5. Conclusion
1. Introduction
1.1. Diabetes Type 1
1.2. Diabetes Type 2
2. Need for Medicinal Plant Discovery for Type 2 Diabetes
3. Methods for Searching for Type 2 Diabetes Active Plants
3.1. Ethnomedical search for plants to treat Type 2 diabetes
3.2. Field research methods for identifying plant to manage type 2 diabetes
3.3. Field studies on efficacy of plants utilized to treat type 2 diabetes
3.4. In vivo animal models for screening, testing and developing plants, extracts and compounds to
treat type 2 diabetes
3.5. Masoprocol: an example of an investigational drug candidate for type 2 diabetes derived from
traditional knowledge.
3.5.1. Pre clinical studies
3.5.2. Safety studies
Medicinal Plants For The Prevention And Treatment Of Coronary Heart Disease 75
Gail B. Mahady, Department of Pharmacy Practice, Program for Collaborative Research in the
Pharmaceutical Sciences, UIC/NIH Center for Botanical Dietary Supplements Research, University of
Illinois at Chicago, USA.
1. Introduction
1.1. Coronary Heart Disease and treatment
2. Artichoke (Cynara scolymus).
2.1. Clinical studies
2.2. In vitro and in vivo studies
3. Garlic (Allium sativum)
3.1. Clinical studies
3.1.1. Antihypercholesterolemic activity
3.1.2. Antihypertensive activity
3.1.3. Effects on platelet aggregation and myocardial infarction
4. Guggul (Commiphora mukul)
4.1. Clinical studies
4.1.1. Antihyperlipidemic effects
5. Ginkgo (Ginkgo biloba)
5.1. Clinical studies
5.1.1. Antioxidant activity
5.1.2. Inhibition of Platelet Aggregation
5.1.3. Hematological effects
5.2. In vitro and in vivo studies
5.2.1. Antioxidant and antiplatelet activities
5.2.2. Enhancement in coronary blood flow
5.2.3. Vasodilatation
5.2.4. Inhibition of Platelet Aggregation and Thrombus Formation
5.2.5. Blood Pressure Regulation
6. Hawthorn (Crataegus species)
6.1. Clinical studies
6.1.1. Cardiac insufficiency
6.2. In vitro and in vivo studies
6.2.1. Inotropic effects
6.2.2. Antiarrhyythmic effects
6.2.3. Ischemic-reperfusion injury
6.2.4. Vasodilation and coronary blood flow
6.2.5. Antihypertensive effects
6.2.6. Antioxidant effects
7. Red wine (Vitis vinifera) and resveratrol
7.1. In vitro studies
7.1.1. Effects on nitric oxide
7.1.2. Effects on infectious components
8. Saffron (Crocus sativus)
8.1. Clinical studies
8.1.1. Antioxidant effects
8.2. In vitro and in vivo studies
8.2.1. Antiatherosclerotic effects.
8.2.2. Antihypertensive activity.
1. Introduction
1.1 Neurodegenerative disease in perspective
1.2. Searching for symptoms in traditional medicine
1.3. Approaches to scientific investigation
1.4. Plants as a source of useful therapeutic agents in neurodegenerative diseases
2. Plants and their constituents from Ayurvedic medicine
2.1 Withania somnifera
2.2. Bacopa monniera
2.3. Centella asiatica
2.4. Mucuna pruriens
3. Plants and their constituents from Chinese traditional medicine (TCM)
3.1. Huperzia serrata
3.2 Ginkgo biloba
3.3 Salvia miltiorrhiza
3.4. Soya
4. Plants and their constituents from European herbal medicine
4.1. Galantamine
4.2. Salvia spp.
4.3. Ergot and its alkaloids
5. Plants and constituents from African and South American traditional medicine
5.1. Physostigma venenosum
5.2. Ptychopetalum olacoides
5.3. Banisteriopsis caapi
6. Conclusions
1. Introduction
1.1. Definitions and Scope
1.2. Cross-Disciplinary Perspectives
2. Shamanism, Psychoactive Plants, and the Origins of Religion
2.1. Trance and Altered States of Consciousness
2.2. Evidence from Ancient Art
3. Psychoactive Botanicals: A World Overview
3.1. Africa
3.1.1. Coffea arabica: The Wine of Islam
3.1.2. Tabernanthe iboga: Way to the Ancestors
3.2. Europe and Asia
3.2.1. Amanita muscaria: Divine Mushroom of Immortality?
3.2.2. Claviceps paspali: Key to the Eleusinian Mysteries?
3.2.3. Atropa belladona, Datura metel, Hyoscyamus niger: Nightshades for Oracles, Witches,
and Beautiful Ladies.
3.2.4. Cannabis sativa: Hemp for Fiber, Medicine, and Delight
3.3. Oceania
3.3.1. Piper methysticum: Kava-kava
3.3.2. Boletus manicus: Kuma Mushroom Madness
3.4. The Americas
1. Introduction
2. Animal self-medication and ethnomedicine
3. The impact of parasites on the evolution of self-medicative behavior
4. Food as medicine in animals and humans
5. Use of plants as medicine by chimpanzees in the wild
5.1. Whole leaf swallowing and the physical expulsion of parasite
5.2. Vernonia amygdalina and bitter pith chewing behavior
5.3. The ethnomedicine and phytochemistry of bitter pith chewing
6. A link between animal self-medication and ethnomedicine
7. Tongwe ethnozoology and health care
8. Future studies and directions of research
1. Introduction
2. Indigenous Plants in Western Medicine
2.1. Plants from Indigenous African Medical Systems
2.2. Plants from other Medical Traditions
2.3. The Case of Artemisia annua L.
3. Biodiversity and Sustainability
3.1. Taxus brevifolia and Biodiversity
3.2. The Case of Rauvolfia spp.
3.3. Prunus africana
3.4. Indigenous Strategies
4. Safety and Efficacy of Medicines
5. Pharmaceutical Anthropology
5.1. Indigenous Interpretations of Medicines
5.2. Injections: Skepticism towards Biomedicine
5.3. Accessibility and Distribution of Medicines
6. Conclusion
1. Introduction
2. Conservation and Sustainable Use of Medicinal Plants
3. Equity Issues in the Medicinal Plant Trade
4. The Botanical Medicine Industry
4.1. Overview of the Market
4.2. The Use of Traditional Knowledge in Product Development, Formulation and Marketing
4.3. Raw Material Sourcing
4.4. Certification of Raw Materials
5. The Pharmaceutical Industry
5.1. Overview of Markets and the Role of Natural Products
5.2. The Use of Traditional Knowledge in R&D
5.3. Raw Material Sourcing
6. Conclusion
Index 271
VOLUME XV
Biological Science Foundations 1
Ralph Kirby, Department of Biochemistry and Microbiology, Rhodes University, Grahamstown, South
Africa.
1. Introduction
2. The Beginning of Modern Biological Science
2.1. What Is Biological Life?
2.2. Microscopic Life
2.3. The Origin of Life
2.4. Evolution and the Origin of Species
3. Genetics and Evolution
3.1. Genetics in the Modern World
3.2. The Mechanisms Involved in Evolution
3.3. Humanity, the Environment, and Evolution
3.4. Artificial Evolution
4. The Molecular Basis of Life
4.1. The Cell
4.2. The Gene
4.3. The Biochemical Processes of Life
4.4. Genetic Manipulation
5. The Molecular Tree of Life
5.1. Morphological Methods of Classifying Species
5.2. Biochemical Methods of Classifying Species
5.3. Gene-Based Classification
5.4. Life on Earth Over the Last 4 Billion Years
6. The Limits of Life on Earth
a. Water as a Limiting Factor
b. Ionic Concentration as a Limiting Factor
c. Temperature as a Limiting Factor
d. Acidity/Alkalinity as a Limiting Factor
e. Gaseous Atmosphere as a Limiting Factor
f. Energy as a Limiting Factor
g. The Edges of the Envelope
7. Life Elsewhere in the Universe
7.1. Is Carbon-Based Life Alone?
7.2. Carbon-Based Life on the Planets
7.3. Carbon-Based Life in Other Star Systems
7.4. Panspermia
8. Conclusion
1. Proteins
1.1. Amino acids
1.2. Polypeptide chains
1.3. Primary structure
1.4. Secondary structure
1.5. Tertiary structure
1.6. Quaternary structure
1.7. Enzymes
2. Carbohydrates
2.1. Monosaccarides
2.1.1. Stereo-isomerization
2.1.2. Cyclic Structures
2.2. Disaccharides
3. Polysaccharides
4. Lipids
4.1. Fatty acids
4.2. Fatty acids in humans
4.3. Triacyglycerols
4.4. Phospholipids
4.5. Steroids
5. Nucleic Acids
5.1. Nucleotides
5.2. The nucleic acids
5.2.1. DNA
5.2.2. DNA can have different structural features
5.2.3. RNA
Carbon Fixation 51
Joanna E Burgess, Department of Biochemistry, Microbiology and Biotechnology, Rhodes University,
Grahamstown, South Africa.
Brett I Pletschke, Department of Biochemistry, Microbiology and Biotechnology, Rhodes University,
Grahamstown, South Africa.
1. Introduction
2. Carbon fixation in higher plants
2.1. The Light Dependent Reactions of Plant Photosynthesis
2.2. The Light Independent Reactions of Photosynthesis: Synthesis of Carbohydrates
2.3. C3, C4 and CAM metabolism
3. Algae
4. Bacteria
4.1. Purple Bacteria
4.2. Green Sulfur Bacteria
4.3. Green Gliding Bacteria
4.4. Heliobacteria
5. Global photosynthesis and the atmosphere
1. Introduction
2. Cellular Anaerobic Respiration
2.1. Glycolysis
2.2. Formation of Acetyl Coenzyme A through the Transition Reaction
2.3. The Citric Acid Cycle
3. The Electron Transport Chain and Chemiosmosis
4. Fermentation
4.1. Glycolysis During Fermentation
4.2. Fermentation End Products
4.3. Precursor Metabolites: Linking Catabolic and Anabolic Pathways
4.4. Anaerobic Respiration in Animals
5. Anaerobic Metabolism and Humankind.
5.1. Waste Treatment
5.2. The Role of Anaerobic Digestion
5.3. Feedstocks
5.4. Products
6. Future Direction
6.1. Food Production and Manufacture of Goods
6.2. Lactic Acid Fermentation
6.3. Alcohol Fermentation
6.4. Fermentation in Industry
6.5. Fermentation in Biotechnology
6.6. Synthetic Rubber
Biochemistry 113
Thomas Traut, Department of Biochemistry & Biophysics, University of North Carolina at Chapel Hill,
USA
1. Introduction
1.1 Basic Concepts and Definitions
2. Central Metabolism
2.1. Sugars and Carbohydrates
2.1.1. Problems of Hyperglycemia
2.2. Amino Acids and Proteins
2.3. Fats and Lipids
2.4. Nucleotides
2.5. Ribonucleic Acids (RNAs)
2.6. Modeling Networks in Central Metabolism
2.6.1 Networks in Hepatocytes
2.6.2 Yeast Metabolic Networks
2.6.3 Networks for Drug Metabolism
2.7. Future Research in Metabolism
3. Deoxyribonucleic Acid (DNA)
3.1. General Features of DNA
3.2. Transcription of DNA
3.3. Regulation of Transcription
3.4. Regulatory RNAs
3.5. Duplicated Genes Provide Isozymes
3.6. Gene Regulation
3.6.1. Variable Splicing of the hnRNA
3.6.2. Natural Time Clocks
3.7. Identifying Genes
3.7.1. Probing Blots from Electrophoresis
3.7.2. DNA Fingerprinting
3.7.3. Microarrays
3.8. Future Research in DNA
3.8.1. The Emergence of Introns
3.8.2. Mutations and Cancer
3.8.3. Epigenetic Regulation or Inheritance
4. Proteins and Enzymes
4.1. Post-translational Processing
4.2. The General Limits for Enzymes
4.2.1. Metabolites are Metastable
4.2.2. Enzymes are Specific
4.3. Types of Enzymatic Reactions
4.4. Types of Cofactors for Catalysis
4.5. Regulation of Enzyme Catalysis
4.6. Future Research for Proteins and Enzymes
4.6.1. An Algorithm to Predict the Structure of a Protein From Its Sequence
4.6.2. Completely Define Post-translational Processing
4.6.3. An Algorithm to Predict the Function of a Protein From Its Sequence
1. Introduction
2. Historical background
3. The philosophy of model chemistry
4. The role of metal cofactors
4.1. The Metals of Biology
4.1.1. Iron
4.1.2. Zinc
4.1.3. Copper
4.1.4. Molybdenum and Tungsten
4.1.5. Nickel
4.1.6. Vanadium
4.1.7. Alkali and Alkaline Earth Cations
5. The role of special metal cofactors
5.1. Tetrapyrroles
5.1.1. Hemes
5.1.2. Chlorophylls
5.1.3. Corrins
5.1.4. Coenzyme F430
5.2. Metalloclusters
5.2.1. Iron-sulfur Clusters
5.2.2. Complex Metalloclusters
5.2.2.1. Metalloclusters in Nitrogenases
5.2.2.2. Metalloclusters in Hydrogenases
5.2.2.3. Metalloclusters in Nitrous Oxide Reductase
5.2.2.4. The Metallocluster of the Oxygen-evolving Center of Photosystem II
5.2.2.5. Metalloclusters in Carbon Monoxide Dehydrogenase/Acetyl Coenzyme A
Synthase
1. From molecules to living systems: complexity is obtained from simple building blocks
2. Amino acids and proteins
2.1. Proteogenic Amino Acids
2.2. Non Proteinogenic Amino Acids
2.3. Amino Acid Polymers: Proteins. Their Structure and Function
2.3.1. Proteins Folding and Structure
2.3.2. Proteins Function and Regulation
3. Nucleotides and nucleic acids: information, energy transport, catalysis
3.1. Chemical Structures of Nucleotides
3.2. Nucleotide Polymers: RNA and DNA
3.2.1. The Flow of Genetic Information
3.2.2. DNA: Storage and Transmission of Information
3.2.3. RNA: Expression of Information and Catalysis
1. Introduction
1.1. The first cell
2. Origin of Eukaryotes
3. Cellular differentiation in multicellular organisms
3.1. Plants
3.2. Animals
4. Eukaryotic cell structure
5. Organization of eukaryotic cells
5.1. Plasma membrane
5.2. Extracellular matrices
5.3. Protein synthesis and transport
5.4. Cytoskeleton and movement
5.5. Nucleus
5.5.1 Genomes
5.5.2 Gene expression
5.5.3 Maintaining the genome
5.6. Organelles
6. The cell cycle
6.1. Mitosis
6.2. Meiosis
7. Regulation of cell growth
7.1. Signal transduction
7.2. Programmed cell death
7.3. Cancer
8. Experimental models
8.1. Yeast
8.2. Arabidopsis
8.3. Drosophila
8.4. The mouse
8.5. Cell culture
8.6. Separation of cellular contents
8.7. Tracing biochemical pathways
9. Future investigations
Index 281
VOLUME XVI
Cell Morphology And Organization 1
Michelle Gehringer, Department of Biochemistry and Microbiology, University of Port Elizabeth, South
Africa
1. Introduction
1.1. The cytoplasm
1.2. Membranes
1.2.1 Structure
1.2.2 The cell cortex
1.2.3 Transmembrane proteins
1.2.4 Endoplasmic reticulum
1.2.5 Golgi apparatus
1.2.6 Lysosomes
1.3. Extracellular matrices
1.3.1 Glycocalyx
1.3.2 Cell walls
1.4. Cytoskeleton
1.4.1 Microfilaments or Actin filaments
1.4.2 Intermediate filaments
1.4.3 Microtubules
1.5. Cilia and Flagella
1.6. Connections between cells
1.6.1 Plasmodesmata
1.6.2 Desmosomes
1. The nucleus
1.1 The nuclear membrane
1.2 The nuclear pore
1.2.1 Structure of the nuclear pore
1.2.2 Function of the nuclear pore
1.3 The lamina
2. The genome
3. Chromosomes
3.1. The nucleosome
3.1.1. Histones
3.1.2. DNA condensation
3.2. Functional domains
3.2.1. Centromere
3.2.2. Telomere
4. DNA replication
4.1. Origin of replication
4.2. DNA polymerases
4.3. Nucleosome replication
5. Nucleolus
5.1. rRNA genes and expression
5.2. Ribosome assembly and export
6. Transcription
6.1. RNA polymerases
6.2. Eukaryote promotors
1. Introduction
2. The distribution and function of the mitochondrion
2.1 The structure of the mitochondrion
2.2 The mitochondrial genome
2.3 The mitochondrial genetic code and translation mechanism
2.4 Maternal inheritance of the mitochondrion
3. Distribution and structure of the chloroplast
3.1 The chloroplast genome
3.2 The chloroplast genetic code
3.3 Maternal inheritance of the chloroplast
4. An endosymbiotic origin for the mitochondrion and chloroplast
4.1 Evolution of the mitochondrion
4.2 Evolution of the Chloroplast
4.3 Other possibly endosymbiotic organelles
5. Conclusions
1. Introduction
2. Signal molecules
2.1 Transmembrane signals for large signal molecules
2.2 Small signal molecules
3. Switches of intracellular molecules
3.1 Regulation of signal molecules
4. Cell surface receptors
4.1 Ion-channel-linked receptors
4.2 G-protein-linked receptors
4.2.1 General structure and function of G-protein-receptors.
4.2.2 G-proteins and ion-channels
4.2.3 G-proteins and enzymes.
4.3 Enzyme-linked receptors
4.3.1 Protein tyrosine kinases
4.3.2 Signaling domains SH2 and SH3.
4.3.3 Ras/MAPK pathway.
4.4 The JAK/STAT pathway
5. Cancer
5.1. Ras proto-oncogenesis
5.2. Signal transduction
5.3 Kinases
5.4 Insertions, deletions and translocations
5.5 Viral oncogenesis
5.5.1 DNA viruses
5.5.2 RNA viruses
5.6 Tumor suppressor genes
6. Conclusion
1. Introduction
2. Inference of interaction networks from expression information
3. Network analysis
4. Dynamic modeling
5. Conclusions
Microbiology 115
Ralph Kirby , Department of Life Science, National Yang Ming University, Peitou, Taipei, Taiwan
1. Introduction
2. Taxonomy
2.1 Morphology
2.1.1 Eucaryote Microorganisms - Protozoa
2.1.2 Eucaryote Microorganisms - Algae
1. Introduction
2. Nucleoid
3. Cytoplasmic Matrix
3.1. Ribosomes
3.2. Plasmids, episomes and bacteriophage
3.3. Inclusion bodies and storage granules
3.4. Endospores
3.5. Intracytoplasmic membranes
4. The Cell Envelope
4.1. Cytoplasmic Membrane
4.2. The Periplasmic Space
4.3. The Cell Wall
4.4. The Outer Membrane
5. Components Exterior to the Cell Wall
5.1 EPS
5.2 Flagella
5.3 Pili
5.4 Fimbriae
6. Differentiation and multicellularity
6.1. Differentiation in Actinomycetes
6.2. Multicellularity and differentiation in cyanobacteria
6.3. Differentiation in Myxobacteria
1. Introduction
2. The Archae, Cyanobacteria, Green phototrophs, and Deeply Branching Genera
2.1. Thermoprotei, Sulfolobi and Barophiles
2.2. The Methanogens
2.3. The Halobacteria
2.4. The Thermoplasms
2.5. The Thermococci
2.6. Aquifex and relatives
2.7. Thermotogas and Geotogas
2.8. The Deinococci
2.9. Thermi
2.10. Chrysiogenes
2.11. The Chlorflexi and Herpetosiphons
2.12. Thermomicrobia
2.13. Prochloron and the Cyanobacteria
2.14. Chlorobia
3. Proteobacteria
3.1 The α -Proteobacteria
3.2. The β Proteobacteria
3.3. The γ Proteobacteria
3.4. The δ Proteobacteria
3.5. The ε Proteobacteria
4. The low G+C gram-positives
5. The high G+C gram-positives
6. The Planctomycetes, Spirochetes, Fibrobacter, Bacteroides and Fusobacteria
6.1. The Planctomycetes
6.2. The Spirochetes
6.3. The Fibrobacters
6.4. The Bacteroides
6.5. The Flavobacteria
6.6. The Sphingobacteria, Flexibacteria and Cytophaga
6.7. The Fusobacteria
1. Introduction
2. Bacterial Cell Growth and Division
3. The bacterial cell cycle and its regulation
4. Bacterial Population Growth
5. Bacterial Nutrition
5.1. Carbon sources and assimilation
5.2. Nitrogen sources and assimilation
5.3. Phosphate sources and assimilation
5.4. Sulfur sources and assimilation
5.5 Nutrient reserves
6. Energy generation
6.1 Aerobic respiration
6.2. Anaerobic respiration
6.3. Fermentation
6.4. Photosynthesis
7. Bacterial Nutrient Stress Responses
Index 251
VOLUME XVII
An Introductory Treatise on Biophysics 1
M.I.El Gohary, Faculty of Science, Al Azhar University, Cairo, Egypt
1. Introduction
1.1 Definition of Biophysics
1.1.1 Classification of Biophysics
1.1.1.1 Physical Biophysics (“True” Biophysics)
1.1.1.2 Physico-Chemical Biophysics (Biophysical Chemistry)
1.1.1.3 Physiological Biophysics (Physical Physiology)
1.1.1.4 Mathematical Biophysics
1.2 Characteristics of Life
1.2.1 Reproduction
1.2.2 Growth
1.2.3 Metabolism
1.2.4 Movement
1.2.5 Responsiveness
1.3 A Few Biological Generalizations
1.3.1 Cellular Organization
1.3.2 Cellular Division
1.3.3 What Causes Cells to Divide?
1.3.4 Cell Differentiation
1.3.5 Organ Regeneration
1.3.6 Biological Classification
2. Chemistry Of Living Systems
2.1 Chemical Bonds
2.1.1 Types of Bonds
2.1.2 Bond Strengths
2.1.2.1 Making and Breaking Bonds
2.1.3 Free Energy
2.1.4 Bonds and Molecular Shapes
2.2 Subunits of Macromolecules
2.3 Biological Macromolecules
2.3.1 Proteins
2.3.1.1 Structure
2.3.2 Prediction, Interaction, and Design of Macromolecules
2.3.3 Protein folding
2.3.4 Enzymes
2.3.5 Nucleic acids (DNA and RNA Chains)
2.3.5.1 DNA
2.3.5.2 Ribonucleic acid (RNA)
3. Biological Energy
18.1 Proteomics
18.2 Genes were easy
18.3 Proteo-factories
18.4 New Protein Atlas
19. Regulation Mechanisms
19.1 The Control Systems of the Body
19.2 Examples of Control Mechanisms
19.2.1 Regulation of Oxygen and Carbon Dioxide Concentrations in the Extracellular Fluid
19.2.2 Regulation of Sodium Ion Concentration
19.2.3 Regulation of Arterial Pressure
19.2.4 Regulation of Calcium/Calmodulin Dependent Signaling
19.3 Characteristics of Control Systems
19.3.1 Negative Feedback Nature of Control Systems
19.3.2 Amplification or Gain of a Control System
19.3.3 Positive Feedback as a Cause of Death—Vicious Cycle
19.3.4 Fast and Slow Positive Feedback Loops
1. Introduction
2. Specificity of mathematical modeling of living systems
3. Basic models in mathematical biophysics
3.1. Unlimited growth. Exponential growth: Auto-catalysis
3.2. Limited growth: The Verhulst equation
3.3. Constraints with respect to a substrate. The models of Monod and Michaelis–Menten
3.4. Competition. Selection
3.5. The Jacob and Monod trigger system
3.6. Classic Lotka–Volterra models
3.7. Models of species interaction
3.8. Models of enzyme catalysis
3.9. Model of a continuous microorganism culture
3.10. Age structure of populations
3.10.1. Continuous models of the age structure
4. Oscillations and rhythms in biological systems
4.1. Oscillations in Glycolysis
4.2. Intracellular calcium oscillations
4.3. Cellular cycles
5. Spatio-temporal self-organization of biological systems
5.1. Waves of life
5.2. Autowaves and dissipative structures
5.3. The basic ‘Brusselator’ model
5.4. Models of morphogenesis
5.5. The Belousov–Zhabotinskii (BZ) reaction
5.6. Theory of nerve conductivity
6. Physical and mathematical models of biomacromolecules
6.1. Molecular dynamics
6.2. Models of DNA Dynamics
7. Modeling of complex biological systems
7.1. Metabolic control analysis
7.2. Mathematical models of primary photosynthetic processes
8. Conclusions
Index 301